2-(Aryl-2-yl)morpholines and their deuterated derivatives, preparation methods and applications
Deuterated (aryl-2-yl)morpholine compounds targeting TAAR1 and 5-HT1A receptors provide a novel approach to treat schizophrenia by enhancing both positive and negative symptoms with reduced side effects, addressing the limitations of current antipsychotic drugs.
Patent Information
- Application Number
- JP2024525952
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-09
- Filing Date
- 2022-11-04
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current antipsychotic drugs for schizophrenia have limited efficacy in improving both positive and negative symptoms and are associated with significant side effects, necessitating the development of novel therapeutic targets that address both symptom types without extrapyramidal side effects.
The use of compounds targeting the trace amine-associated receptor 1 (TAAR1) and 5-HT1A receptor, specifically deuterated derivatives of (aryl-2-yl)morpholine, as potential therapeutic agents for schizophrenia, which are designed to improve both positive and negative symptoms while minimizing side effects.
These compounds demonstrate potential in effectively treating schizophrenia by targeting TAAR1 and 5-HT1A receptors, offering improved therapeutic outcomes for both positive and negative symptoms with reduced side effects.
Smart Images

Figure 2024542057000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of biopharmaceuticals, and more particularly to the use of 2-(aryl-2-yl)morpholines in the treatment of schizophrenia, and their deuterated derivatives, preparation methods and applications. [Background technology]
[0002] Schizophrenia is the most prevalent psychiatric illness, with a slow course and a tendency to repeat attacks, severe symptoms, or exacerbations, resulting in serious disease burdens and poor outcomes for patients and their families. Patients with schizophrenia exhibit positive symptoms such as delusions, hallucinations, and disorders of thought, speech, and behavior, negative symptoms such as blunted affect and facial expression, poor speech, and anhedonia, as well as cognitive impairment. Over the past few decades, the development and clinical application of anti-schizophrenic drugs has made great strides, but conventional antipsychotics (first generation) (haloperidol, droperidol, thioridazine, etc.) and atypical antipsychotics (second generation) (clozapine, risperidone, olanzapine, aripiprazole, etc.) both inhibit D2 and 5-HT 2A It targets the target mechanism, has a high therapeutic effect on positive symptoms, but is not ideal for improving negative symptoms and cognitive impairment, and has side effects such as extrapyramidal and weight gain. Anti-schizophrenia drugs include GlyT1 D1, D4, D3, NMDA, mGluR2 / 3, AMPA 5-HT 2C Many non-D2 / 5-HT antagonists, including nicotinic a7, muscarinic M1 / M4, H3, and NK-3. 2A There is also research into the receptors. These targets show good therapeutic efficacy in preclinical models, but most of the novel non-D2 / 5-HT 2A Mechanistic drugs have shown limited efficacy or no success in clinical trials, so there is a strong need to develop new targeted drugs for anti-schizophrenia that can improve not only positive symptoms but also negative symptoms and cognitive impairment, without extrapyramidal side effects.
[0003] Trace amines (TAs) are low in concentration in mammalian brains, and their contents are altered in many psychiatric disorders (schizophrenia, depression, anxiety, Parkinson's disease / attention deficit hyperactivity disorder). TAAR1 receptors are a subtype of TA1 receptors and belong to the G protein-coupled receptor family. They are mainly expressed in peripheral organs and cells (e.g., stomach, small intestine, duodenum, and leukocytes) and in the presynaptic membranes of axon terminals of astrocytes and monoamine neurons in the central nervous system (CNS), and function in regulating DA, 5-HT, and glutamatergic activity.
[0004] 5-HT 1A The receptor is a member of the G protein-coupled receptor family and a subtype of the 5-HT receptor. It is distributed in the central and peripheral regions and is closely related to the mind, mood, learning and memory. 5-HT receptors are found in the frontal and temporal cortex of patients with schizophrenia. 1A The density of 5-HT receptors increases 1A Activation of the receptor can improve the negative symptoms of schizophrenia, and studies have found that it is also associated with improvement in the positive symptoms.
[0005] Currently, the international application WO-2011069063A2 is a TAAR1 receptor agonist and inhibits 5-HT 1A SEP-363856, a receptor partial agonist, is used to treat schizophrenia, and has shown good results in Phase II clinical trials, is effective for both positive and negative symptoms, has high safety, and is currently undergoing Phase III clinical research. In order to meet the huge market needs, there is an urgent need to develop a drug with a new target for treating schizophrenia that is effective for both positive and negative symptoms and has high safety. Summary of the Invention
[0006] In one aspect, the object of the present invention is to provide the use of the following compound, its stereoisomer or its pharma- ceutically acceptable salt in the manufacture of a medicament for the treatment of a disease associated with TAAR1: [ka] [ka]
[0007] In another aspect, the object of the present invention is to provide a compound represented by general formula (I), its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the structure of the compound represented by general formula (I) is as follows: [ka] R1, R2, R3, R4, R5 and R9 each independently represent hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Deuterated alkyl groups, C 1-6 Deuterated alkoxy group, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, optionally further substituted; R 6a , R 6b , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium; n is 0, 1, 2 or 3; As a condition, R1, R2, R3, R4, R5, R9, R 6a , R 6b , R 7a , R 7b , R 8a and R 8b At least one of the substituents contains D.
[0008] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further represented by general formula (I-1) or (I-2): [ka] In some embodiments of the present invention, R1, R2, R3, R4, R5 and R9 are each independently selected from hydrogen, deuterium, halogen, amino group, hydroxy group, cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Deuterated alkyl groups, C 1-6 Deuterated alkoxy group, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, optionally selected from deuterium, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Deuterated alkyl groups, C 1-6 Deuterated alkoxy group or C 1-6 may be further substituted with a halogenated alkyl group, and R1, R2, R3, R4, R5 and R9 are each preferably independently hydrogen, deuterium, fluorine, chlorine, a methyl group, a deuterated methyl group, a deuterated methoxy group or a cyclopropyl group, and R1, R2, R3, R4, R5 and R9 are each more preferably independently hydrogen, deuterium, a methyl group, fluorine, -OCD3 or -N(CH3)2; R 6a , R 6b , R 6a’ , R 6b’ , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium; As a condition, R1, R2, R3, R4, R5, R9, R 6a , R 6b , R 6a’ , R 6b’ , R 7a , R 7b , R 8a and R 8b At least one of the substituents contains D.
[0009] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further represented by general formula (I-3) or (I-4): [ka] R1, R2, R3, R4, R5, R9, R 7a , R 7b and R9 are as shown in general formula (I-1) or (I-2).
[0010] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further represented by the general formula (II): [ka] R1, R2 and R5 each independently represent hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, or C 1-3 Alkyl group, C 1-3 Alkoxy group, C 1-3 Deuterated alkyl groups, C 1-3 Deuterated alkoxy group, C 1-3 Halogenated alkyl groups and C 1-3 alkylamino groups; R 7a and R 7b are each independently selected from hydrogen or deuterium; R1, R2, R5, R 7a and R 7b At least one of the substituents contains D.
[0011] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further represented by general formula (II-1): [ka] R 7a and R 7b are each independently selected from hydrogen or deuterium.
[0012] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is represented by the general formula (II-1), which further represents the general formula (II-1-a) or (II-1-b): [ka] As shown in the figure.
[0013] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further represented by general formula (II-2): [ka] R1 and R2 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, or C 1-3 Alkyl group, C 1-3 Alkoxy group, C 1-3 Deuterated alkyl groups, C 1-3 Deuterated alkoxy group, C 1-3 Halogenated alkyl groups and C 1-3 alkylamino groups; Preferably, R1 and R2 are each independently selected from hydrogen, deuterium, fluorine, chlorine, a dimethylamino group, a methyl group, a methoxy group, a deuterated methyl group, and a deuterated methoxy group.
[0014] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is such that the general formula (II-2) is further represented by the general formula (II-2-a) or (II-2-b): [ka] As shown in the figure.
[0015] Another object of the present invention is to provide a compound represented by general formula (I'), its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the structure of the compound represented by general formula (I') is as follows: [ka] In some embodiments of the present invention, R1, R2, R3, R4, R5, R 6a , R 6b , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium, with the proviso that R1, R2, R3, R4, R5, R 6a , R 6b , R 7a , R 7b , R 8a and R 8b At least one of the substituents is selected from D.
[0016] In some embodiments of the present invention, R1, R2, R3, and R4 are each independently selected from hydrogen, deuterium, halogen, amino, hydroxy, cyano, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, R5, R 6a , R 6b , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium; As a condition, R1, R2, R3, R4, R5, R 6a , R 6b , R 7a , R 7b , R 8a and R 8b is not hydrogen at the same time, R1, R2, R3 and R4 are each independently a halogen, a cyano group, a hydroxyl group, an amino group, or 1-6 Alkyl group or C 1-6 When selected from halogenated alkyl groups, R, R 6a , R 6b , R 7a , R 7b , R 8a and R 8bAt least one of is selected from deuterium.
[0017] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further represented by the general formula (II'): [ka] Where: R1, R2, R3 and R4 each independently represent hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, and At least one of R1, R2, R3, and R4 is a deuterium, a deuterated methyl group, or a cyclopropyl group.
[0018] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further as shown in general formula (III): [ka] Where: R1, R2, R3 and R4 each independently represent hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, R 6a , R 6b , R 7a and R 7b are each independently selected from hydrogen or deuterium.
[0019] In a further preferred embodiment of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt is further as shown in general formula (IV): [ka] Where: R 6a , R 6b , R 7a and R 7b are each independently selected from hydrogen or deuterium, and at least two groups are deuterium; R1, R2, R3 and R4 each independently represent hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 The cycloalkyl group is selected from the group consisting of cycloalkyl groups.
[0020] In a further preferred embodiment of the present invention, R1, R2, R3 and R4 in any of the above general formulas are each independently selected from hydrogen, deuterium, halogen, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, Preferred are hydrogen, deuterium, fluorine, chlorine, a methyl group, a deuterated methyl group, and a cyclopropyl group.
[0021] Another object of the present invention is to provide a compound represented by general formula (V), its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the structure of the compound represented by general formula (V) is as follows: [ka] Where: M is N or CR a is selected from R a R1, R2, R3 and R4 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, R5, R 7a and R 7b are each independently selected from hydrogen or deuterium, at least one of which is deuterium.
[0022] In a further preferred embodiment of the present invention, the general formula (V) further comprises the general formula (VI): [ka] or a stereoisomer or a pharma- ceutically acceptable salt thereof, M is selected from N or CH; R1, R2, R3 and R4 are each independently hydrogen, deuterium, halogen, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 The cycloalkyl group is selected from the group consisting of cycloalkyl groups.
[0023] In a further preferred embodiment of the present invention, R1 and R2 are each independently selected from halogen, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, and R3 and R4 are each hydrogen.
[0024] In a further preferred embodiment of the present invention, R1 and R2 are each independently fluorine, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, and R3 and R4 are each hydrogen.
[0025] In a further preferred embodiment of the present invention, the general formula (V) is further represented by the general formula (VI-1) or the general formula (VI-2): [ka] The compound is as shown in the following formula (1):
[0026] In a further preferred embodiment of the present invention, the general formula (I') further comprises the general formula (Va): [ka] The compound is as shown in the following formula (1):
[0027] In a further preferred embodiment of the present invention, the general formula (I') further represents the general formula (VI-a): [ka] or a stereoisomer or a pharma- ceutically acceptable salt thereof, R1, R2, R3 and R4 are each independently hydrogen, deuterium, halogen, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 The cycloalkyl group is selected from the group consisting of cycloalkyl groups.
[0028] In a further preferred embodiment of the present invention, R1 and R2 are each independently selected from halogen, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, and R3 and R4 are each hydrogen.
[0029] In a further preferred embodiment of the present invention, R1 and R2 are each independently fluorine, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, and R3 and R4 are each hydrogen.
[0030] In a further preferred embodiment of the present invention, the general formula (VI-a) further represents the general formula (VI-a-1) or the general formula (VI-a-2): [ka] The compound is as shown in the following formula (1):
[0031] Another object of the present invention is to provide a compound represented by general formula (VII), a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, wherein the structure of the compound represented by general formula (VII) is [ka] As stated above, R1 and R2 are each independently hydrogen, deuterium, a halogen, a hydroxyl group, a cyano group, or C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, preferably halogen or C 1-3 It is an alkyl group.
[0032] In a further preferred embodiment of the present invention, the compound of general formula (VII), its stereoisomer or its pharma- ceutically acceptable salt is further represented by general formula (VII-1) or general formula (VII-2): [ka] As shown in the figure.
[0033] In a preferred embodiment of the present invention, the disease associated with TAAR1 is a neurological disorder, and the neurological disorder is selected from schizophrenia, social dysfunction or psychosis, preferably, schizophrenia is selected from schizophrenia spectrum disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, paranoid schizophrenia, schizophreniform personality disorder or schizotypal personality disorder, preferably, psychosis is selected from delusional disorder, brief psychotic disorder, shared psychotic disorder, mental disorder due to physical illness, medication-induced psychosis, psychological and emotional disorder, aggression, mental confusion, excited psychosis, Tourette's syndrome, organic or NOS psychosis, seizures, agitation, post-traumatic stress disorder, behavioral confusion, The condition is selected from a neurodegenerative disease, Alzheimer's disease, Parkinson's disease, movement disorder, Huntington's disease, dementia, affective disorder, anxiety disorder, affective psychosis, depression, major depressive disorder, malaise, bipolar disorder, mania, seasonal affective disorder, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, dizziness, epilepsy, pain, neuropathic pain, neuropathic pain sensitivity state, inflammatory pain, fibromyalgia, migraine, cognitive impairment, movement disorder, restless legs syndrome, multiple sclerosis, sleep disorder, sleep apnea, lethargy attacks, excessive daytime sleepiness, jet lag, drowsiness side effect of medication, insomnia, substance abuse dependency, addiction, eating disorder, sexual dysfunction, hypertension, vomiting, Lesche-Nyhane disease, hepatolenticular degeneration, autism, or premenstrual dysphoria.
[0034] In a preferred embodiment of the present invention, the single dose range of the compound, its stereoisomer or its pharma- ceutically acceptable salt (based on the free base) is 1 to 1000 mg, preferably 1 to 500 mg, and exemplary doses are 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47 mg, 48 mg, 49 mg, 50 mg, 51 mg, 52 mg, 53 mg, 54 mg, 55 mg, 56 mg, 57 mg, 58 mg, 59 mg, 60 mg, 61 mg, 62 mg, 63 mg, 64 mg, 65 mg, 66 mg, 67 mg, 68 mg, 69 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg, 75 mg, 76 mg, 77 mg, 78 mg, 79 mg, 80 mg, 81 mg, 82 mg, 83 mg, 84 mg, 85 mg, 86 mg, 87 mg, 88 mg, 89 mg, 90 mg, 91 mg 4mg, 45mg, 46mg, 47mg, 48mg, 49mg, 50mg, 52.5mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 9 0mg, 95mg, 100mg, 105mg, 110mg, 120mg, 130mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg.
[0035] In a preferred embodiment of the present invention, the administration frequency of the compound, its stereoisomer or its pharma- ceutically acceptable salt is once a day, twice a day, three times a day, once a week, twice a week or three times a week; In a preferred embodiment of the present invention, the compound, its stereoisomer, or a pharma- ceutically acceptable salt thereof is administered once a day, and the single dose is 1 to 500 mg, preferably 1 to 300 mg, more preferably 1 to 200 mg, even more preferably 5 to 100 mg, and even more preferably 20 to 100 mg.
[0036] The dosages according to the invention may be in free base or salt form, and unless otherwise specified, dosages are calculated in free base form. One skilled in the art will recognize that dosages of the invention will vary depending on the disease being treated, the severity of the disease, the route of administration, the sex, age, and general health of the subject, the use of excipients, the possibility of co-administration with other therapeutic methods (e.g., the use of other drugs), and the judgment of the treating physician.
[0037] In a preferred embodiment of the invention, the route of administration of the compound, its stereoisomer or its pharma- ceutically acceptable salt is selected from intramuscular, intravenous, subcutaneous, transdermal, intradermal, intranasal, oral or sublingual.
[0038] In another aspect, the present invention provides a method for preparing a compound represented by general formula (VI), a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, comprising: [ka] The method includes the steps of: subjecting compound (VI-a) to an acylation reaction to prepare compound (VI-b), subjecting compound (VI-c) to ring formation under basic conditions, subjecting compound (VI-d) to deuteration, subjecting compound (VI) to deprotection, and optionally further preparing a pharma- ceutically acceptable salt thereof; wherein X is selected from halogen, P is selected from amino protecting groups, and R1, R2, R3 and R4 are as defined in general formula (VI).
[0039] In a preferred form of the invention, X is chlorine and P is a Boc protecting group.
[0040] The present invention further relates to pharmaceutical compositions, which comprise a therapeutically effective amount of any of the foregoing general formulas and specific compounds, stereoisomers thereof, or pharma- ceutically acceptable salts thereof, and one or more pharma- ceutically acceptable carriers, diluents, or excipients.
[0041] In a preferred embodiment of the invention, the pharmaceutical composition is selected from a tablet, a capsule, a liquid formulation or an injectable solution.
[0042] In a preferred embodiment of the invention, the pharmaceutical composition is an immediate release formulation or a sustained release formulation.
[0043] In a preferred form of the invention, the pharmaceutical composition comprises a filler, optionally the pharmaceutical composition comprises a disintegrant, optionally the pharmaceutical composition comprises an adhesive, optionally the pharmaceutical composition comprises a surfactant, preferably the pharmaceutical composition comprises one or more of a filler, a disintegrant, an adhesive, a surfactant, a sweetener, a flow agent or a lubricant.
[0044] In a preferred embodiment of the present invention, the weight percentage of the compound, its stereoisomer, or its pharma- ceutically acceptable salt in the pharmaceutical composition is 0.1-99%, 1-95%, 2-90%, 3-80%, 5-75%, 5-60%, 5-50%, or 5-40% based on the free base.
[0045] In some embodiments of the present invention, the weight percentage of the compound, its stereoisomer, or its pharma- ceutically acceptable salt in the pharmaceutical composition is 1-10%, 10-20%, 20-30%, 15-30%, 20-50%, 40-70%, or 50-70%, based on the free base.
[0046] In some embodiments of the invention, the pharmaceutical composition contains a unit dose of the compound, its stereoisomer, or its pharma- ceutically acceptable salt, based on the free base, of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, 20 mg, 21 mg, 22 mg, 23 mg, 24 mg, 25 mg, 26 mg, 27 mg, 28 mg, 29 mg, 30 mg, 31 mg, 32 mg, 33 mg, 34 mg, 35 mg, 36 mg, 37 mg, 38 mg, 39 mg, 40 mg, 41 mg, 42 mg, 43 mg, 44 mg, 45 mg, 46 mg, 47mg, 48mg, 49mg, 50mg, 52.5mg, 55mg, 60mg, 65mg, 70mg, 75mg, 80mg, 85mg, 90mg, 95mg, 100mg, 105mg, 110mg, 120mg, 130mg, 140mg, 150mg, 160mg, 170mg, 180mg, 190mg, 200mg, 210mg, 220mg, 230mg, 240mg, 250mg, 260mg, 270mg, 280mg, 290mg, 300mg, 350mg, 400mg, 450mg, 500mg, 550mg, 600mg, 650mg, 700mg, 750mg, 800mg, 850mg, 900mg, 950mg, 1000mg.
[0047] In some embodiments of the present invention, the compound, its stereoisomer or its pharma- ceutically acceptable salt may be administered in any convenient manner, for example, orally, parenterally, buccal, sublingually, nasally, rectally, intrathecally or transdermally, and in a correspondingly prepared pharmaceutical composition.
[0048] In some embodiments of the invention, the compound, its stereoisomer, or its pharma- ceutically acceptable salt may be formulated as a liquid or solid preparation, for example, a syrup, suspension, emulsion, tablet, capsule, powder, granule, or lozenge.
[0049] Furthermore, in some embodiments of the present invention, the specific structure of the compound is [ka] [ka] [ka] As follows.
[0050] The present invention further relates to the application of any of the above general formulas and specific compounds, their stereoisomers or their pharma- ceutically acceptable salts, or the above pharmaceutical compositions in the manufacture of medicines for treating diseases related to TAAR1.
[0051] The present invention further relates to the application of any of the above general formulas and specific compounds, their stereoisomers or pharma- ceutically acceptable salts, or the above pharmaceutical compositions in the manufacture of TAAR1 agonist medicaments.
[0052] The present invention further relates to the application of any of the above general formulas and specific compounds, their stereoisomers or pharma- ceutically acceptable salts thereof, or pharmaceutical compositions thereof, in the manufacture of a medicament for treating, preventing or controlling a neurological disorder, wherein the neurological disorder is selected from schizophrenia, social dysfunction or psychosis, preferably, the schizophrenia is selected from schizophrenia spectrum disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, paranoid schizophrenia, schizoid personality disorder or schizotypal personality disorder, preferably, the psychosis is selected from delusional disorder, brief psychotic disorder, shared psychotic disorder, mental disorder due to physical illness, medication-induced psychosis, psycho-emotional disorder, aggression, mental confusion, agitated psychosis, Tourette's syndrome, organic or NOS psychosis, seizures, agitation, post traumatic stress disorder, behavioral confusion, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, movement disorders, Huntington's disease, dementia, affective disorders, anxiety disorders, affective psychosis, depression, major depressive disorder, malaise, bipolar disorder, mania, seasonal affective disorder, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, dizziness, epilepsy, pain, neuropathic pain, neuropathic pain sensitivity state, inflammatory pain, fibromyalgia, migraine, cognitive impairment, movement disorders, restless legs syndrome, multiple sclerosis, sleep disorders, sleep apnea, lethargy attacks, excessive daytime sleepiness, jet lag, drowsiness side effect of medication, insomnia, substance abuse dependence, addiction, eating disorders, sexual dysfunction, hypertension, vomiting, Lesche-Nyhane disease, hepatolenticular degeneration, autism or premenstrual dysphoria.
[0053] The present invention further relates to a method for preventing and / or treating a disease associated with TAAR1, which comprises administering to a patient a therapeutically effective amount of any of the above general formulas and specific compounds, their stereoisomers or their pharma- ceutically acceptable salts, or pharmaceutical compositions thereof.
[0054] The present invention further provides a method of treating a disease condition using a compound or pharmaceutical composition of the present invention, including, but not limited to, a condition associated with impaired TAAR1 function.
[0055] The present invention further relates to a method for treating a TAAR1-associated disease in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the present invention or a pharma- ceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. In one embodiment, said mammal is a human.
[0056] In some embodiments, the method is for treating schizophrenia, schizophrenia spectrum disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, paranoid schizophrenia, schizoid personality disorder, schizotypal personality disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, mental disorder due to physical illness, medication-induced psychosis, psychological and emotional disorder, aggression, confusion, excited psychosis, Tourette's syndrome, organic or NOS psychosis, seizures, agitation, post-traumatic stress disorder, behavioral confusion, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, movement disorder, Huntington's disease, dementia, affective disorder, anxiety disorder, The present invention relates to the treatment of affective psychosis, depression, major depressive disorder, dysphoria, bipolar disorder, mania, seasonal affective disorder, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, dizziness, epilepsy, pain, neuropathic pain, neuropathic pain sensitivity state, inflammatory pain, fibromyalgia, migraine, cognitive impairment, movement disorder, restless legs syndrome, multiple sclerosis, sleep disorder, sleep apnea, lethargy attacks, excessive daytime sleepiness, jet lag, lethargic side effects of drugs, insomnia, substance abuse dependency, addiction, eating disorders, sexual dysfunction, hypertension, vomiting, Lesche-Nyhane disease, hepatolenticular degeneration, autism or premenstrual dysphoria, and preferably to the treatment of schizophrenia.
[0057] Unless stated to the contrary, terms used in the specification and claims have the following meanings.
[0058] The term "alkyl group" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 8 carbon atoms, more preferably an alkyl group containing 1 to 6 carbon atoms, and most preferably an alkyl group containing 1 to 3 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, and 5-methylhexyl. , 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof.More preferably, it is a lower alkyl group containing 1 to 6 carbon atoms, and non-limiting examples include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, a sec-butyl group, an n-pentyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a 2-methylbutyl group, a 3-methylbutyl group, an n-hexyl group, a 1-ethyl-2-methylpropyl group, a 1,1,2-trimethylpropyl group, a 1,1-dimethylbutyl group, a 1,2-dimethylbutyl group, a 2,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a 2-ethylbutyl group, a 2-methylpentyl group, a 3-methylpentyl group, a 4-methylpentyl group, and a 2,3-dimethylbutyl group. The alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available binding site, and said substituent is preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate groups, and in the present invention is preferably methyl, ethyl, isopropyl, tert-butyl, halogenated alkyl, deuterated alkyl, alkyl substituted with alkoxy and alkyl substituted with hydroxy.
[0059] The term "alkylene group" refers to an alkyl group in which one hydrogen atom is further substituted, e.g., a "methylene group" refers to -CH2-, an "ethylene group" refers to -(CH2)2-, a "propylene group" refers to -(CH2)3-, a "butylene group" refers to -(CH2)4-, etc. The term "alkenyl group" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, e.g., vinyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, etc. An alkenyl group may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl groups, alkenyl groups, alkynyl groups, alkoxy groups, alkylthio groups, alkylamino groups, halogens, mercapto groups, hydroxy groups, nitro groups, cyano groups, cycloalkyl groups, heterocycloalkyl groups, aryl groups, heteroaryl groups, cycloalkoxy groups, heterocycloalkoxy groups, cycloalkylthio groups, and heterocycloalkylthio groups.
[0060] The term "cycloalkyl group" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the ring of the cycloalkyl group containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc., and polycyclic cycloalkyl groups include spiro, fused and bridged cyclic cycloalkyl groups, preferably cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl and cycloheptyl.
[0061] The term "alkoxy group" refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), where the definition of alkyl group is as set forth above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, and cyclohexyloxy groups. An alkoxy group may be optionally substituted or unsubstituted, and if substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl, or carboxylate groups.
[0062] "Halogenated alkyl group" refers to an alkyl group that is substituted with one or more halogens, where the alkyl group is as defined above.
[0063] A "halogenated alkoxy group" refers to an alkoxy group substituted with one or more halogens, where alkoxy is as defined above.
[0064] "Hydroxyalkyl group" refers to an alkyl group substituted with a hydroxy group, where the alkyl group is as defined above.
[0065] A "hydroxy group" refers to an -OH group.
[0066] "Halogen" refers to fluorine, chlorine, bromine or iodine.
[0067] An "amino group" refers to -NH2.
[0068] A "cyano group" refers to -CN.
[0069] A "nitro group" refers to --NO.sub.2.
[0070] A "carbonyl group" refers to -C(O)-.
[0071] A "carboxyl group" refers to -C(O)OH.
[0072] "THF" refers to tetrahydrofuran.
[0073] The various terms "X is selected from A, B, or C", "X is selected from A, B and C", "X is A, B or C", "X is A, B and C" and the like all mean the same thing, i.e., X can be one or more of A, B, C.
[0074] Any hydrogen atom described in the present invention may be replaced with its isotope, deuterium, and any hydrogen atom in the compounds of the examples of the present invention may also be replaced with a deuterium atom.
[0075] In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 52.5% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 60% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 67.5% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 75% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 82.5% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 90% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 95% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 97% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 97.5% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 98% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 99% deuterium incorporation. In some embodiments, in the compounds of the invention, each designated deuterium atom has at least 99.5% deuterium incorporation.
[0076] "Optionally" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and the description includes cases where the event or circumstance has occurred or not occurred. For example, "a heterocyclyl group optionally substituted with an alkyl group" means that the alkyl group may, but need not, be present, and the description includes cases where the heterocyclyl group is substituted with an alkyl group and cases where the heterocyclyl group is not substituted with an alkyl group.
[0077] "Substituted" refers to the substitution of one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group, with the corresponding number of substituents, independently of each other. Needless to say, the substituents are only present in their possible chemical positions, and the skilled person can determine (experimentally or theoretically) possible or impossible substitutions without much effort. For example, amino or hydroxy groups with free hydrogen may be unstable if they are attached to carbon atoms with unsaturated (e.g., olefinic) bonds.
[0078] A "pharmaceutical composition" is meant to contain a mixture of one or more compounds described herein or physiologically / pharmaceutical acceptable salts or prodrugs thereof with other chemical components, as well as other components such as physiologically / pharmaceutical acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism and facilitate absorption of the active ingredient(s), thereby exerting a biological activity.
[0079] The pharmaceutical compositions of the present invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. In some embodiments, the compounds of the general formula herein are administered transdermally (e.g., using a transdermal patch or iontophoresis therapy technology). Other formulations can be readily provided in unit dosage form, such as tablets, sustained release capsules and liposomes, and can be prepared by any method well known in the pharmaceutical art.
[0080] "Pharmaceutically acceptable salt" "Pharmaceutically acceptable salt" refers to salts of compounds of the present invention which are safe and effective when used in a mammalian body and possess the desired biological activity. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0081] The present invention will now be further described in conjunction with the following examples, which are not intended to limit the scope of the present invention.
[0082] Working Example The structures of the compounds of the present invention are established by nuclear magnetic resonance (NMR) or / and liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker AVANCE-400 nuclear magnetometer, with deuterated dimethylsulfoxide (DMSO-d6), deuterated methanol (CD3OD) and deuterated chloroform (CDCl3) as solvents and tetramethylsilane (TMS) as internal standard.
[0083] The liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 1200 Infinity Series mass spectrometer. The HPLC was performed using an Agilent 1200DAD high pressure liquid chromatograph (Sunfire C18 150×4.6 mm chromatography column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C 18 A 150 x 4.6 mm chromatography column is used.
[0084] Thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate, TLC uses 0.15mm-0.20mm specifications, thin layer chromatography separation and purification of products uses 0.4mm-0.5mm specifications. Column chromatography generally uses Yantai Yellow Sea silica gel 200-300 mesh silica gel as the carrier.
[0085] The starting materials in the embodiments of the present invention are either known and commercially available, or can be synthesized using or according to methods known in the art.
[0086] Unless otherwise specified, all reactions of the present invention are carried out under a dry nitrogen or argon gas atmosphere with continuous magnetic stirring, the solvents are dry solvents, and the reaction temperatures are in degrees Celsius.
[0087] Compound A 2-(pyridin-2-yl)morpholine [ka]
[0088] Step 1: 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-one 2-Bromo-1-(2-pyridyl)ethanone hydrobromide (30g, 0.11mol) was dissolved in 150mL of N,N-dimethylformamide, potassium carbonate (36.8g, 0.27mol) was added, then 2-(benzylamino)ethanol (17.8g, 0.12mol) was added, and the mixture was stirred at room temperature for 18 hours. 200mL of water was added to the reaction solution, and the mixture was extracted with ethyl acetate (150mL x 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain the title product 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-one (17g, brown liquid), with a yield of 58.9%. MS m / z(ESI):271.1 [M+1]
[0089] Step 2: 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-ol 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-one (15g, 55.5mmol) was dissolved in 200mL of anhydrous ethanol, sodium borohydride (2.7g, 72mmol) was added in small portions, and the mixture was stirred at room temperature for 2 hours. 200mL of saturated ammonium chloride was added to the reaction solution to quench the reaction, ethanol was removed under reduced pressure, the aqueous phase was extracted with ethyl acetate (200mL x 3), the organic phase was combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the title product 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-ol (10g, brown liquid), with a yield of 66.2%. MS m / z(ESI):273.1 [M+1]
[0090] Step 3: 4-benzyl-2-(pyridin-2-yl)morpholine 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-ol (1.1 g, 4 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran, sodium hydride (0.2 g, 8 mmol) was added in small portions, and the mixture was stirred at room temperature for 1 hour to react. 1-toluenesulfonyl-1H-imidazole (1.0 g, 4.5 mmol) was added in small portions under ice bath, and the mixture was stirred at room temperature for 18 hours to react. 50 mL of water was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (50 mL x 3), and the organic phase was combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain the title product 4-benzyl-2-(pyridin-2-yl)morpholine (0.4 g, colorless gel), with a yield of 38.9%. MS m / z(ESI):255.1 [M+1]
[0091] Step 4: 2-(pyridin-2-yl)morpholine 4-benzyl-2-(pyridin-2-yl)morpholine (0.4 g, 1.6 mmol) was dissolved in 10 mL of anhydrous dichloromethane, 1-chloroethyl chloroformate (0.34 g, 2.4 mmol) was added, and the reaction was stirred at room temperature for 4 hours. The solvent was spin-dried, 5 mL of methanol was added, and the reaction was stirred at reflux for 1 hour. The reaction was cooled to room temperature, the solvent was spin-dried, 10 mL of saturated sodium carbonate solution was added to the reaction, the aqueous phase was extracted with ethyl acetate (20 mL x 3), the organic phase was combined, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated under reduced pressure, and the crude was purified by column chromatography to give the title product 2-(pyridin-2-yl)morpholine (0.18 g, colorless gel), with a yield of 69.7%. MS m / z(ESI):165.1 [M+1]
[0092] Example 1 2-(pyridin-2-yl)morpholine-2-d Step 1: 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-one [ka]
[0093] 2-Bromo-1-(2-pyridyl)ethanone (30 g, 106.8 mmol, HBr) and 2-(benzylamino)ethanol (17.876 g, 117.5 mmol) were dissolved in N,N-dimethylformamide (150 mL), potassium carbonate (36.8 g, 267.0 mmol) was added and the reaction was stirred at room temperature for 18 h. Ammonium chloride solution (1000 mL) was added, the aqueous phase was extracted with EA (500 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry and the crude was purified by column chromatography to give 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-one (17 g). Yield 59%. MS m / z(ESI):271.14[M+1]
[0094] Step 2: 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-d-1-ol-d [ka]
[0095] 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-one (12 g, 44.4 mmol) was dissolved in tetrahydrofuran (150 mL) and lithium hydrogen aluminum deuteride (3.7 g, 88.8 mmol) was added at 0° C. and the reaction was stirred at room temperature for 18 hours. The reaction was quenched by adding sodium sulfate decahydrate, diluted with ethyl acetate, filtered, the filter cake was washed with ethyl acetate, the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude was purified by column chromatography to give 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-d-1-ol-d (3.98 g). The yield is 32.8%. MS m / z(ESI):274.16[M+1]
[0096] Step 3: 4-benzyl-2-(pyridin-2-yl)morpholine-2-d [ka]
[0097] 2-(benzyl(2-hydroxyethyl)amino)-1-(pyridin-2-yl)ethan-1-d-1-ol-d (4 g, 14.6 mmol) was dissolved in tetrahydrofuran (40 mL), purged with nitrogen gas, sodium hydride (1.2 g, 30.6 mmol, 60% purity) was added, and the reaction was stirred at room temperature for 1 hour. It was cooled to 0° C., 1-(p-toluenesulfonyl)imidazole (3.9 g, 17.5 mmol) was added in portions, and the reaction was allowed to warm slowly to room temperature and stirred for 18 hours. Saturated aqueous ammonium chloride solution (50 mL) was added, the aqueous phase was extracted with ethyl acetate (50 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude was purified by column chromatography to give 4-benzyl-2-(pyridin-2-yl)morpholine-2-d (1.4 g). The yield is 37.6%. MS m / z(ESI):256.15 [M+1]
[0098] Step 4: 2-(pyridin-2-yl)morpholine-2-d [ka]
[0099] 4-Benzyl-2-(pyridin-2-yl)morpholine-2-d (1.4 g, 5.5 mmol) was dissolved in anhydrous dichloromethane (30 mL), 1-chloroethyl chloroformate (2.4 g, 16.5 mmol) was added, and the reaction was stirred at room temperature for 18 hours. The solvent was spun off to give 2-(pyridin-2-yl)morpholine-2-d (0.9 g). The yield was 99.4%. It was used directly in the next step reaction. 1 H NMR(400MHz,DMSO-d6):δ 8.50-8.48(m,1H),7.80-7.76(m,1H),7.43-7.41(m,1H),7.29-7.26(m,1H),3.91-3.8 8(m,1H),3.66-3.59(m,1H),3.12-3.09(m,1H),2.76-2.71(m,2H),2.52-2.49(m,2H). MS m / z(ESI):166.10[M+1].
[0100] Step 5: (S)-2-(pyridin-2-yl)morpholine-2-d and (R)-2-(pyridin-2-yl)morpholine-2-d [ka]
[0101] 2-(pyridin-2-yl)morpholine-2-d (0.9 g, 5.5 mmol) was dissolved in dichloromethane (30 mL), triethylamine (2.8 g, 27.2 mmol) and di-tert-butyl dicarbonate (2.4 g, 10.9 mmol) were added and the reaction was stirred at room temperature for 18 hours. Water (30 mL) was added, the aqueous phase was extracted with dichloromethane (30 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry and the crude was purified by column chromatography to give tert-butyl 2-(pyridin-2-yl)morpholine-4-carboxylate-2-d (0.8 g), 55.4% yield. The compounds were then separated using a chiral column (chromatographic column: CHIRALCEL OD 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=70:30, run time (min): 8, linear mode: isocratic) to give compound 1-P1 (300mg, RT(retention time)=2.487min) and compound 1-P2 (300mg, RT(retention time)=3.377min). MS m / z(ESI):266.15 [M+1]
[0102] Compound 1-P1 or compound 1-P2 (0.3 g, 1.1 mmol) was dissolved in 1'4-dioxane (1 mL), hydrochloric acid / dioxane (4 M, 5 mL) was added, and the reaction was stirred at room temperature for 1 hour. The solvent was spin-dried, saturated aqueous sodium bicarbonate solution (1 mL) was added, and the mixture was extracted with dichloromethane (3 mL*3). The organic phase was extracted with an oil pump, and compound 1-1 (200 mg) was obtained from compound 1-P1, and compound 1-2 (200 mg) was obtained from compound 1-P2. Compound 1-1: 1 H NMR(400MHz,DMSO-d6):δ 8.50-8.48(m,1H),7.80-7.76(m,1H),7.43-7.41(m,1H),7.29-7.26(m,1H),3.91-3.8 8(m,1H),3.66-3.59(m,1H),3.12-3.09(m,1H),2.76-2.71(m,2H),2.52-2.49(m,2H). MS m / z(ESI):166.10[M+1]. Compound 1-2: 1 H NMR(400MHz,DMSO-d6):δ 8.50-8.48(m,1H),7.80-7.76(m,1H),7.43-7.41(m,1H),7.29-7.26(m,1H),3.91-3.8 8(m,1H),3.66-3.59(m,1H),3.12-3.09(m,1H),2.76-2.71(m,2H),2.52-2.49(m,2H). MS m / z(ESI):166.10[M+1].
[0103] Example 2 2-(pyridin-2-yl)morpholine-5,5-d2 [ka]
[0104] Starting from 2-(benzylamino)ethan-2,2-d2-1-ol, the product 2-(pyridin-2-yl)morpholine-5,5-d2 was obtained with reference to Example 1. MS: 167.10 [M+1].
[0105] Example 3 2-(pyridin-2-yl)morpholine-5,5,6,6-d4 [ka]
[0106] Starting from 2-(benzylamino)ethan-1,1,2,2-d4-1-ol, the product 2-(pyridin-2-yl)morpholine-5,5,6,6-d4 was obtained with reference to Example 1. MS: 169.10 [M+1].
[0107] Example 4 2-(6-Cyclopropylpyridin-2-yl)morpholine [ka]
[0108] Step 1: 1-(6-cyclopropylpyridin-2-yl)ethan-1-one [ka]
[0109] At room temperature, 1-(6-bromo-2-pyridyl)ethanone (6.0 g, 30.00 mmol), cyclopropylboronic acid (3.86 g, 44.99 mmol), Pd(dppf)Cl2.CH2Cl2 (1.23 g, 1.50 mmol), potassium phosphate (15.92 g, 74.99 mmol) were dissolved in tetrahydrofuran (60 mL), purged with nitrogen gas, heated to 80 ° C, reacted for 4 hours, and cooled to room temperature. LCMS showed the completion of the reaction, the reaction solution was diluted with ethyl acetate, filtered, the filter residue was washed with ethyl acetate, the organic phase was combined, the organic phase was washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude was separated by column chromatography (petroleum ether: ethyl acetate: 10: 1) to obtain the desired product as a colorless oil (3.80 g), the yield is 78.6%. MS: 162.08 [M+1].
[0110] Step 2: 2-Bromo-1-(6-cyclopropylpyridin-2-yl)ethan-1-one [ka]
[0111] At room temperature, 1-(6-cyclopropylpyridin-2-yl)ethan-1-one (1.0 g, 6.20 mmol) was dissolved in HBr / HOAc (6.20 mmol, 6 mL, 33% purity), and liquid bromine (0.99 g, 6.20 mmol, 0.4 mL) was added dropwise, stirred at room temperature for 10 minutes, and heated to 40° C., reacted for 2 hours, cooled to room temperature, the desired product was produced by LCMS, and ether was added, stirred at room temperature for 30 minutes, a solid precipitated, filtered, the solid was washed with ether, and spin-dried to obtain a yellow solid (1.99 g), the yield is 100%. MS:239.99,241.99[M+1].
[0112] Step 3: 2-(benzyl(2-hydroxyethyl)amino)-1-(6-cyclopropylpyridin-2-yl)ethan-1-one [ka]
[0113] At room temperature, 2-bromo-1-(6-cyclopropylpyridin-2-yl)ethan-1-one (1.99 g, 6.20 mmol, hydrobromide salt) was dissolved in N,N-dimethylformamide (20 mL), and potassium carbonate (3.00 g, 21.70 mmol) and 2-(benzylamino)ethanol (1.12 g, 7.44 mmol) were added and stirred at room temperature for 12 hours. TLC showed the completion of the reaction. The reaction solution was diluted with ethyl acetate and washed with saturated sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude was separated by column chromatography (petroleum ether:ethyl acetate=1:1) to obtain the desired product as a yellow oil (0.90 g), with a yield of 46.8%. MS:311.17[M+1].
[0114] Step 4: 2-(benzyl(2-hydroxyethyl)amino)-1-(6-cyclopropylpyridin-2-yl)ethan-1-ol [ka]
[0115] Under ice bath, 2-(benzyl(2-hydroxyethyl)amino)-1-(6-cyclopropylpyridin-2-yl)ethan-1-one (0.9g, 2.90mmol) was dissolved in methanol (10mL) and sodium borohydride (0.13g, 3.48mmol) was added and reacted at room temperature for 1 hour, LCMS showed the completion of the reaction. Spin-dried, the residue was dissolved in ethyl acetate and washed with saturated ammonium chloride solution, saturated sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 70:30 to 30:70) to obtain the target product as a yellow oil (0.55g), the yield is 60.7%. MS:313.17[M+1].
[0116] Step 5: 4-benzyl-2-(6-cyclopropylpyridin-2-yl)morpholine [ka]
[0117] At room temperature, 2-(benzyl(2-hydroxyethyl)amino)-1-(6-cyclopropylpyridin-2-yl)ethan-1-ol (0.55g, 1.76mmol) was dissolved in tetrahydrofuran (5mL), nitrogen gas was replaced, and sodium hydrogen (84.50mg, 3.52mmol, 60%) was added, stirred at room temperature for 1 hour, and 1-(4-toluenesulfonyl)imidazole (0.43g, 1.94mmol) in tetrahydrofuran (2mL) was added dropwise, stirred at room temperature for 2 hours, TLC showed the completion of the reaction, the reaction liquid was quenched with saturated ammonium chloride solution, and extracted with ethyl acetate, the organic phase was combined, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude was separated by preparative thin layer chromatography (PE:EA=4:1) to obtain the desired product as a yellow oil (0.30g), the yield is 57.9%. MS:295.17[M+1].
[0118] Step 6: 2-(6-cyclopropylpyridin-2-yl)morpholine [ka]
[0119] At room temperature, 4-benzyl-2-(6-cyclopropylpyridin-2-yl)morpholine (132.0 mg, 448.38 μmol) was dissolved in dichloromethane (5 mL) and 1-chloroethyl chloroformate (192.32 mg, 1.35 mmol) was added dropwise and stirred at room temperature for 2 hours. Spin-dried and the residue was dissolved in methanol, heated to 70° C., reacted for 1 hour, cooled to room temperature, LCMS showed the reaction was complete, spin-dried and the residue was used directly in the next step (107 mg), yield 99.1%. MS:205.17[M+1].
[0120] Step 7: tert-Butyl 2-(6-cyclopropylpyridin-2-yl)morpholine-4-carboxylate [ka]
[0121] At room temperature, 2-(6-cyclopropylpyridin-2-yl)morpholine (107 mg, 444.48 μmol, hydrochloride salt) was dissolved in dichloromethane (5 mL), and N,N-diethylethylamine (224.89 mg, 2.22 mmol) and tert-butoxycarbonyl tert-butyl carbonate (179.83 mg, 888.97 μmol) were added, and the mixture was stirred at room temperature for 12 hours. LCMS showed the reaction was complete, and the reaction solution was diluted with dichloromethane and washed with saturated sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was separated by preparative thin layer chromatography (PE:EA=10:1) to obtain the desired product as a colorless oil (118 mg), with a yield of 87.2%. MS:249.39[M-55].
[0122] Step 8: (R)-2-(6-cyclopropylpyridin-2-yl)morpholine and (S)-2-(6-cyclopropylpyridin-2-yl)morpholine [ka]
[0123] Compound tert-butyl 2-(6-cyclopropylpyridin-2-yl)morpholine-4-carboxylate was separated by chiral column (chromatography column: CHIRALCEL OD 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=90:10, run time (min): 10, linear mode: isocratic) to obtain compound 4-P1 (0.05g, RT (retention time) = 2.690min) and compound 4-P2 (0.04g, RT (retention time) = 3.410min). Compound 4-P1 was dissolved in 1'4-dioxane, hydrochloric acid / dioxane (4M) was added, and the reaction was stirred at room temperature for 1 hour. The solvent was spun dry, saturated aqueous sodium bicarbonate was added, and the organic phase was extracted with dichloromethane and pumped with an oil pump to give compound 4-1. The Boc protecting group was removed from compound 4-P2 in the same manner to give compound 4-2. Compound 4-1, MS:205.17[M+1]. Compound 4-2, MS:205.17[M+1].
[0124] Example 5 2-(Pyridin-2-yl-6-d)morpholine [ka]
[0125] Step 1: Preparation of 2-(6-chloropyridin-2-yl)morpholine [ka]
[0126] Starting from 1-(6-chloropyridin-2-yl)ethan-1-one, the product 2-(6-chloropyridin-2-yl)morpholine was obtained by the known method (patent WO2015 / 165835). MS: 199.06 [M+1].
[0127] Step 2: 2-(pyridin-2-yl-6-d)morpholine [ka]
[0128] 2-(6-chloropyridin-2-yl)morpholine (300 mg, 1.51 mmol) and cesium carbonate (980 mg, 3.02 mmol) were dissolved in deuterated methanol (7 mL), and 1,1'-bisdiphenylphosphinoferrocenedichloropalladium (110.38 mg, 0.15 mmol) was added under the protection of nitrogen gas. The mixture was stirred at 80°C and reacted for 16 hours. The reaction solution was evaporated to dryness, and the crude product was separated by high-speed liquid chromatography to obtain the product 2-(pyridin-2-yl-6-d)morpholine (35 mg, 14.0% yield). MS:166.10[M+1].
[0129] Example 6 (R)-2-(pyridin-2-yl-5-d)morpholine and (S)-2-(pyridin-2-yl-5-d)morpholine [ka]
[0130] Step 1: Preparation of 2-bromo-1-(5-chloropyridin-2-yl)ethan-1-one [ka]
[0131] 1-(5-chloropyridin-2-yl)ethan-1-one (10 g, 64.3 mmol) was dissolved in carbon tetrachloride (100 mL), liquid bromine (10.3 g, 64.3 mmol) was added, and the reaction was stirred for 18 hours at 70° C. The solvent was spun dry, water (30 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give crude 2-bromo-1-(5-chloropyridin-2-yl)ethan-1-one (15 g, 99.5% yield).
[0132] Step 2: Preparation of 2-(benzyl(2-hydroxyethyl)amino)-1-(5-chloropyridin-2-yl)ethan-1-one [ka]
[0133] The hydrobromide salt of 2-bromo-1-(5-chloropyridin-2-yl)ethan-1-one (15 g, 64.0 mmol) and 2-(benzylamino)ethanol (10.6 g, 70.4 mmol) were dissolved in N,N-dimethylformamide (200 mL), potassium carbonate (22.1 g, 160 mmol) was added, and the reaction was stirred for 18 hours at 25° C. Water (1000 mL) was added, the aqueous phase was extracted with ethyl acetate (500 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude was separated by silica gel column chromatography to give the title product 2-(benzyl(2-hydroxyethyl)amino)-1-(5-chloropyridin-2-yl)ethan-1-one (11 g, 56.4% yield). MS m / z(ESI):305.1 [M+H]
[0134] Step 3: Preparation of 2-(benzyl(2-hydroxyethyl)amino)-1-(5-chloropyridin-2-yl)ethan-1-ol [ka]
[0135] 2-(benzyl(2-hydroxyethyl)amino)-1-(5-chloropyridin-2-yl)ethan-1-one (11 g, 36.1 mmol) was dissolved in ethanol (200 mL), sodium borohydride (1.78 g, 46.9 mmol) was added portionwise, and the reaction was stirred at 20° C. for 2 hours. The solvent was spun dry, water (100 mL) was added, the aqueous phase was extracted with ethyl acetate (100 mL×3), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude was separated by silica gel column chromatography to give the title product 2-(benzyl(2-hydroxyethyl)amino)-1-(5-chloropyridin-2-yl)ethan-1-ol (11 g, 99% yield). MS m / z(ESI):307.1 [M+H]
[0136] Step 4: Preparation of 4-benzyl-2-(5-chloropyridin-2-yl)morpholine [ka]
[0137] 2-(benzyl(2-hydroxyethyl)amino)-1-(5-chloropyridin-2-yl)ethan-1-ol (5 g, 16.3 mmol) was dissolved in tetrahydrofuran (100 mL), purged with nitrogen gas, sodium hydrogen (1.37 g, 34.2 mmol, 60% purity) was added, and the reaction was stirred at this temperature for 1 hour. It was cooled to 0° C., 1-(p-toluenesulfonyl)imidazole (4.35 g, 19.6 mmol) was added in portions, and the reaction was allowed to warm slowly to room temperature and stirred for 18 hours. Saturated ammonium chloride (100 mL) was added, the aqueous phase was extracted with ethyl acetate (100 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude product was separated by silica gel column chromatography to give 4-benzyl-2-(5-chloropyridin-2-yl)morpholine (1.4 g, 29.8% yield). MS m / z(ESI):289.1 [M+H]
[0138] Step 5: Preparation of 4-benzyl-2-(pyridin-2-yl-5-d)morpholine [ka]
[0139] 4-benzyl-2-(5-chloropyridin-2-yl)morpholine (0.8 g, 2.8 mmol), (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium (3.9 mg, 5.3 μmol), and cesium carbonate (2.7 g, 8.3 mmol) were dissolved in deuterated methanol (10 mL), purged with nitrogen gas, and the reaction was stirred at 75° C. for 18 hours. Water (50 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL×2), the organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude product was separated by silica gel column chromatography to give 4-benzyl-2-(pyridin-2-yl-5-d)morpholine (0.6 g, 84.8% yield). MS m / z(ESI):256.1 [M+H]
[0140] Step 6: Preparation of 2-(pyridin-2-yl-5-d)morpholine [ka]
[0141] 4-Benzyl-2-(pyridin-2-yl-5-d)morpholine (0.6 g, 2.4 mmol) and 1-chloroethyl chloroformate (1.0 g, 7.1 mmol) were dissolved in dichloromethane (10 mL) and the reaction was stirred for 18 hours at 15° C. The solvent was spun off to give crude 2-(pyridin-2-yl-5-d)morpholine (0.38 g, 97.9% yield). MS m / z(ESI):166.1 [M+H].
[0142] Step 7: Preparation of tert-butyl 2-(pyridin-2-yl-5-d)morpholine-4-carboxylate [ka]
[0143] 2-(pyridin-2-yl-5-d)morpholine (0.38 g, 2.30 mmol) was dissolved in dichloromethane (10 mL), N,N-diethylethylamine (1.16 g, 11.50 mmol), di-tert-butyl dicarbonate (1.5 g, 6.9 mmol) were added, and the reaction was stirred for 2 hours at 10° C. Water (30 mL) was added, the aqueous phase was extracted with ethyl acetate (30 mL×2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude product was isolated by silica gel column chromatography to give tert-butyl 2-(pyridin-2-yl-5-d)morpholine-4-carboxylate (0.5 g, 81.9% yield). The compounds were then separated by chiral column (chromatographic column: CHIRALCEL OD-H 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=70:30, run time (min): 8, linear mode: isocratic) to give product P1, (200mg, RT(retention time)=2.490min, yield: 32.8%) and product P2 (200mg, RT(retention time)=3.373min, yield: 32.8%). P1, MS m / z(ESI):266.1 [M+1] P2, MS m / z(ESI):266.1 [M+1]
[0144] Step 8: Preparation of (R)-2-(pyridin-2-yl-5-d)morpholine and (S)-2-(pyridin-2-yl-5-d)morpholine [ka]
[0145] tert-Butyl 2-(pyridin-2-yl-5-d)morpholine-4-carboxylate P1 (0.2 g, 0.75 mmol) and P2 (0.2 g, 0.75 mmol) were dissolved in 1',4-dioxane (1 mL), hydrochloric acid / dioxane (4 M, 4 mL) was added, and the reaction was stirred at room temperature for 1 h. The solvent was spun dry, water and 4 M aqueous hydrochloric acid were added, lyophilized, saturated aqueous sodium bicarbonate was added, extracted with dichloromethane, and the organic phase was pumped out with an oil pump to give the title products 6-1 (120 mg, 96% yield) and 6-2 (120 mg, 96% yield). 6-1: MS m / z(ESI): 166.1[M+H]+. 6-2: MS m / z(ESI): 166.1[M+H]+
[0146] Example 7 (R)-2-(pyridin-2-yl-4-d)morpholine and (S)-2-(pyridin-2-yl-4-d)morpholine [ka]
[0147] Using 1-(4-chloropyridin-2-yl)ethan-1-one as a raw material, product tert-butyl 2-(pyridin-2-yl-4-d)morpholine-4-carboxylate was obtained by referring to Example 6. The compound was then separated by chiral column (chromatography column: CHIRALCEL OD-H 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=70:30, run time (min): 8, linear mode: isocratic) to obtain product P1, (RT (retention time) = 2.490min, product P2 (RT (retention time) = 3.373min).
[0148] Refer to step 8 of Example 6 to obtain products 7-1 and 7-2. Compound 7-1 MS:166.1[M+1]. Compound 7-2 MS:166.1[M+1].
[0149] Example 8 2-(pyridin-2-yl-3-d)morpholine [ka]
[0150] Starting from 1-(3-chloropyridin-2-yl)ethan-1-one, the product 2-(pyridin-2-yl-3-d)morpholine was obtained according to Example 5. MS:166.10[M+1].
[0151] Example 9 2-(6-methylpyridin-2-yl)morpholine-2-d [ka]
[0152] Starting from 1-(6-methylpyridin-2-yl)ethan-1-one, the product 2-(6-methylpyridin-2-yl)morpholine-2-d was obtained by referring to Step 2 of Example 4 and Example 1.
[0153] MS:180.12[M+1].
[0154] Example 10 2-(6-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0155] Step 1: 2-Methyl-6-(oxiran-2-yl)pyridine [ka]
[0156] Trimethylsulfoxonium iodide (17.7 g, 86.7 mmol) was dissolved in dimethylsulfoxide (100 mL) and tert-butoxide (9.1 g, 80.9 mmol) was added and the reaction was stirred at room temperature for 1 h. A solution of 6-methylpyridine-2-carboxaldehyde (7 g, 57.8 mmol) in dimethylsulfoxide (20 mL) was added and the reaction was stirred at room temperature for 2 h. Water (300 mL) was added and the aqueous phase was extracted with EA (300 mL x 2), the organic phase was washed with saturated brine (300 mL), dried over anhydrous sodium sulfate, filtered, spun dry and the crude was purified by column chromatography to give 2-methyl-6-(oxiran-2-yl)pyridine (6 g) in 76.8% yield.
[0157] Step 2: 2-(benzylamino)-1-(6-methyl-2-pyridyl)ethanol [ka]
[0158] 2-Methyl-6-(oxiran-2-yl)pyridine (6 g, 44.4 mmol) was dissolved in isopropanol (60 mL), phenylmethanamine (5.7 g, 53.3 mmol) was added and the reaction was stirred for 18 h at 80° C. The solvent was spun off, water (100 mL) was added, the aqueous phase was extracted with EA (100 mL×2), the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered, spun off and the crude was purified by column chromatography to give 2-(benzylamino)-1-(6-methyl-2-pyridyl)ethanol (3.8 g), 35.3% yield. MS m / z(ESI):243.14 [M+1]
[0159] Step 3: 4-benzyl-6-(6-methyl-2-pyridyl)morpholin-3-one [ka]
[0160] 2-(benzylamino)-1-(6-methyl-2-pyridyl)ethanol (3.8 g, 15.7 mmol) was dissolved in dichloromethane (50 mL), triethylamine (4.8 g, 47.1 mmol) and 3-chloropropionyl chloride (2.4 g, 18.8 mmol) were added and the reaction was stirred at room temperature for 2 hours. Water (50 mL) was added, the aqueous phase was extracted with dichloromethane (50 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered and spun to dryness to give the crude intermediate. THF (50 mL) was added to the above crude, tert-butoxide (3.4 g, 30.1 mmol) was added and the reaction was stirred at room temperature overnight. Water (50 mL) was added, the aqueous phase was extracted with ethyl acetate (50 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry, and the crude was purified by column chromatography to give 4-benzyl-6-(6-methyl-2-pyridyl)morpholin-3-one (2.2 g), with a yield of 50.0%. MS m / z(ESI):283.14 [M+1]
[0161] Step 4: 4-benzyl-2-(6-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0162] 4-benzyl-6-(6-methyl-2-pyridyl)morpholin-3-one (1.5 g, 5.3 mmol) was dissolved in tetrahydrofuran (30 mL), aluminum trichloride (1.1 g, 8.0 mmol) was added, dissolved by sonication, lithium aluminum hydrogen deuteride (446.3 mg, 10.6 mmol) was added, and the reaction was stirred at room temperature for 1 h. Water (0.5 mL) was added, 15% sodium hydroxide (0.5 mL), water (1.5 mL) was added, stirred for 30 min, filtered, the filter cake was washed with tetrahydrofuran, the organic phase was dried over anhydrous sodium sulfate, filtered, and spun dry to give 4-benzyl-2-(6-methylpyridin-2-yl)morpholin-5,5-d2 (1.2 g), 83.5% yield. MS m / z(ESI):271.17[M+1]
[0163] Step 5: 2-(6-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0164] 4-benzyl-2-(6-methylpyridin-2-yl)morpholine-5,5-d2 (1.2 g, 4.4 mmol) and 1-chloroethyl chloroformate (1.9 g, 13.3 mmol) were dissolved in dichloromethane (10 mL) and the reaction was stirred at room temperature overnight. The solvent was spun off and the crude material was separated by high performance liquid chromatography to give the product 2-(6-methylpyridin-2-yl)morpholine-5,5-d2 (0.5 g), 62.5% yield. 1 H NMR(400MHz,DMSO-d6):δ 7.65(t,1H),7.20(d,1H),7.12(d,1H),4.38-4.35(m,1H),3.89-3.87(m,1 H),3.60-3.58(m,1H),3.11-3.07(m,1H),2.52-2.46(m,1H),2.43(s,3H). MS: 181.12 [M+1].
[0165] Step 6: 2-(6-methylpyridin-2-yl)morpholine-5,5-d2, (R)-2-(6-methylpyridin-2-yl)morpholine-5,5-d2 and (S)-2-(6-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0166] 2-(6-methylpyridin-2-yl)morpholine-5,5-d2 (0.8 g, 4.4 mmol) was dissolved in dichloromethane (20 mL), triethylamine (2.3 g, 22.3 mmol) and di-tert-butyl dicarbonate (1.5 g, 6.7 mmol) were added and the reaction was stirred at room temperature for 1 h. Water (30 mL) was added, the aqueous phase was extracted with dichloromethane (30 mL x 2), the organic phase was dried over anhydrous sodium sulfate, filtered, spun dry and the crude was purified by column chromatography to give tert-butyl 2-(6-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 (1.1 g). The compounds were separated by chiral column (chromatography column: CHIRALCEL OD 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=80:20, run time (min): 8, linear mode: isocratic) to obtain compound 10-P1 (450mg, RT(retention time)=2.730min) and compound 10-P2 (420mg, RT(retention time)=3.830min). MS m / z(ESI):281.12 [M+1].
[0167] Compound 10-P1 or compound 10-P2 (450 mg, 1.6 mmol) was dissolved in 1'4-dioxane (1 mL), hydrochloric acid / dioxane (4 M, 5 mL) was added, and the reaction was stirred at room temperature for 1 hour. The solvent was spin-dried, saturated aqueous sodium bicarbonate solution (1 mL) was added, and the mixture was extracted with dichloromethane (3 mL*3), and the organic phase was removed with an oil pump to obtain compound 10-1 from compound 10-P1 and compound 10-2 (310 mg) from compound 10-P2, respectively. Compound 10-1: 1 H NMR(400MHz,DMSO-d6):δ 7.65(t,1H),7.20(d,1H),7.12(d,1H),4.38-4.35(m,1H),3.89-3.87(m,1 H),3.60-3.58(m,1H),3.11-3.07(m,1H),2.52-2.46(m,1H),2.43(s,3H). MS:181.12[M+H]+ . Compound 10-2:1H NMR(400MHz,DMSO-d6):δ 7.65(t,1H),7.20(d,1H),7.12(d,1H),4.38-4.35(m,1H),3.89-3.86(m,1 H),3.60-3.58(m,1H),3.11-3.07(m,1H),2.52-2.46(m,1H),2.43(s,3H). MS:181.12[M+H] + .
[0168] Example 11 2-(6-methylpyridin-2-yl)morpholine-5,5,6,6-d4 [ka]
[0169] Starting from 1-(6-methylpyridin-2-yl)ethan-1-one and 2-(benzylamino)ethan-1,1,2,2-d4-1-ol, the product 2-(6-methylpyridin-2-yl)morpholine-5,5,6,6-d4 was obtained by referring to step 2 of example 4 and example 1. MS: 183.12 [M+1].
[0170] Example 12 2-(5-chloropyridin-2-yl)morpholine-2-d [ka]
[0171] Starting from 1-(5-chloropyridin-2-yl)ethan-1-one, the product 2-(5-chloropyridin-2-yl)morpholine-2-d was obtained by following the procedure of step 2 in Example 4 and Example 1. MS:200.06[M+1].
[0172] Example 13 2-(5-chloropyridin-2-yl)morpholine-5,5,6,6-d4 [ka]
[0173] Starting from 1-(5-chloropyridin-2-yl)ethan-1-one and 2-(benzylamino)ethan-1,1,2,2-d4-1-ol, the product 2-(5-chloropyridin-2-yl)morpholine-5,5,6,6-d4 was obtained by referring to step 2 of example 4 and example 1. MS:203.08[M+1].
[0174] Example 14 2-(6-(methyl-d3)pyridin-2-yl)morpholine [ka]
[0175] Starting from 1-(6-(methyl-d3)pyridin-2-yl)ethan-1-one, the product 2-(6-(methyl-d3)pyridin-2-yl)morpholine was obtained by following the procedure of step 2 of Example 4 and Example 1. MS: 182.13 [M+1].
[0176] Example 15 2-(5-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0177] Step 1: 2-(5-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 Starting from 5-methylpyridine-2-carboxaldehyde, the product 2-(5-methylpyridin-2-yl)morpholine-5,5-d2 was obtained according to Example 10. MS: 181.12 [M+1].
[0178] Step 2: (R)-2-(5-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 and (S)-2-(5-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 [ka]
[0179] Referring to Example 10, the product tert-butyl-2-(5-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 was obtained. The compound was separated by chiral column (chromatography column: CHIRALCEL OD 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=80:20, run time (min): 10, linear mode: isocratic) to obtain compound 15-P1 (450mg, RT(retention time)=2.730min) and compound 15-P2 (420mg, RT(retention time)=3.867min); With reference to Example 10, the Boc protecting group was removed to obtain compound 15-1 from compound 15-P1, and compound 15-2 from compound 15-P2. Compound 15-1: 1 H NMR(400MHz,DMSO-d6)δ 8.32(s,1H),7.58(dd,1H),7.30(d,1H),4.38(dd,1H),3.87(d,1H),3.60(d,1H),3.07(dd,1H),2.53-2.47(m,1H),2.27(s ,3H). MS: 181.12 [M+1]. Compound 15-2: 1 H NMR(400MHz,DMSO-d6)δ 8.32(s,1H),7.58(dd,1H),7.30(d,1H),4.38(dd,1H),3.87(d,1H),3.59(d,1H),3.07(dd,1H),2.52-2.46(m,1H),2.27(s ,3H). MS: 181.12 [M+1].
[0180] Example 16 2-(4-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0181] Step 1: tert-butyl-2-(4-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 [ka]
[0182] Starting from 4-methylpyridine-2-carboxaldehyde, the product tert-butyl-2-(4-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 was obtained according to Example 10.
[0183] Step 2: (R)-2-(4-methylpyridin-2-yl)morpholine-5,5-d2 and (S)-2-(4-methylpyridin-2-yl)morpholine-5,5-d2 [ka]
[0184] Referring to Example 10, the product tert-butyl-2-(4-methylpyridin-2-yl)morpholine-4-carboxylate-5,5-d2 was obtained. The compound was separated by chiral column (chromatography column: CHIRALCEL AD 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=80:20, run time (min): 10, linear mode: isocratic) to obtain compound 16-P1 (450mg, RT(retention time)=4.290min), compound 16-P2 (420mg, RT(retention time)=4.730min), With reference to Example 10, the Boc protecting group was removed to obtain compound 16-1 from compound 16-P1, and compound 16-2 from compound 16-P2. Compound 16-1: 1 H NMR(400MHz,DMSO-d6)δ 8.32(d,1H),7.25(s,1H),7.09(d,1H),4.38(dd,1H),3.88(d,1H),3.60(d,1H),3.10(dd,1H),2.52-2.46(m,1H),2.31(s ,3H). MS: 181.12 [M+1]. Compound 16-2: 1 H NMR(400MHz,DMSO-d6)δ 8.32(d,1H),7.25(s,1H),7.09(d,1H),4.38(dd,1H),3.88(d,1H),3.60(d,1H),3.10(dd,1H),2.52-2.46(m,1H),2.31(s ,3H). MS: 181.12 [M+1].
[0185] Example 17 2-(5-fluoropyridin-2-yl)morpholine-5,5-d2 [ka]
[0186] Step 1: Preparation of 5-fluoro-2-(oxiran-2-yl)pyridine [ka]
[0187] Trimethylsulfoxonium iodide (79.16g, 359.71mmol) was dissolved in dimethylsulfoxide (300mL), and tert-butoxide (37.67g, 335.73mmol) was added under cooling with an ice-water bath and protection of nitrogen gas. The mixture was stirred at 26°C for 2 hours to react. Under cooling with an ice-water bath and protection of nitrogen gas, 5-fluoropyridine-2-carboxaldehyde (30g, 239.81mmol) was added. The mixture was stirred at 26°C for 2 hours to react. The reaction was quenched by adding saturated saline (250mL) to the mixture, extracted with ethyl acetate (150mL x 3), the organic phase was combined, washed with saturated saline (150mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with petroleum ether:ethyl acetate=100:0 to 90:10) to obtain the desired product 5-fluoro-2-(oxiran-2-yl)pyridine (15.3 g, yield: 45.86%).
[0188] Step 2: Preparation of 2-(benzylamino)-1-(5-fluoro-2-pyridyl)ethanol [ka]
[0189] Under the protection of nitrogen gas, 5-fluoro-2-(oxiran-2-yl)pyridine (15.3 g, 109.97 mmol) was added to benzylamine (35.35 g, 329.91 mmol). The mixture was stirred at 85° C. for 6 hours to react, and then stirred at room temperature for 6 hours. The mixture was concentrated under reduced pressure to remove benzylamine. The residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 100:0 to 20:80) to obtain the target product 2-(benzylamino)-1-(5-fluoro-2-pyridyl)ethanol (22 g, yield: 81.23%). MS:247.1[M+1].
[0190] Step 3: Preparation of N-benzyl-2-chloro-N-[2-(5-fluoro-2-pyridyl)-2-hydroxyethyl]acetamide [ka]
[0191] 2-(benzylamino)-1-(5-fluoro-2-pyridyl)ethanol (22 g, 89.33 mmol) and triethylamine (27.12 g, 267.99 mmol, 37.38 mL) were dissolved in dichloromethane (300 mL), and chloroacetyl chloride (15.13 g, 133.99 mmol, 10.67 mL) was added under cooling with an ice-water bath and protection of nitrogen gas. The mixture was stirred at 0° C. for 2 hours to react. The reaction solution was quenched with saturated saline (130 mL), and the organic phase was separated, washed with saturated saline (50 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude N-benzyl-2-chloro-N-[2-(5-fluoro-2-pyridyl)-2-hydroxyethyl]acetamide (28 g, yield: 97.11%). The crude was used directly in the next step. MS:323.1[M+1].
[0192] Step 4: Preparation of 4-benzyl-6-(5-fluoro-2-pyridyl)morpholin-3-one [ka]
[0193] (N-benzyl-2-chloro-N-[2-(5-fluoro-2-pyridyl)-2-hydroxyethyl]acetamide (28 g, 86.75 mmol) was dissolved in tetrahydrofuran (1000 mL), and tert-butoxide (19.47 g, 173.50 mmol) was added under cooling with an ice-water bath and protection of nitrogen gas. The mixture was stirred at 26 ° C for 12 hours to react. Saturated saline (250 mL) was added to the mixture to quench the reaction, and the organic phase was separated and washed with saturated saline (150 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with petroleum ether: ethyl acetate = 100: 0 to 70: 30) to obtain the target product 4-benzyl-6-(5-fluoro-2-pyridyl)morpholin-3-one (14 g, yield: 56.37%). MS:287.1[M+1].
[0194] Step 5: Preparation of 4-benzyl-5,5-dideutero-2-(5-fluoro-2-pyridyl)morpholine [ka]
[0195] 4-Benzyl-6-(5-fluoro-2-pyridyl)morpholin-3-one (6.5 g, 22.70 mmol) and aluminum trichloride (3.03 g, 22.70 mmol) were dissolved in tetrahydrofuran (150 mL), and lithium aluminum deuteride (953.07 mg, 22.70 mmol) was added under cooling with an ice-water bath and protection with nitrogen gas. The mixture was stirred at 26° C. for 12 hours to react. Under cooling with ice-water bath and protection of nitrogen gas, the mixture was quenched by adding saturated saline (20mL) to the reaction, diluted hydrochloric acid (1N, 20mL) was added, and then 15% aqueous sodium hydroxide solution was added to adjust PH=8-9, filtered, the solid was washed with ethyl acetate (20mL×3), the organic phase was combined, washed successively with saturated saline (100mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the desired product 4-benzyl-5,5-dideutero-2-(5-fluoro-2-pyridyl)morpholine (5.7g, yield: 91.52%), and the crude product was used directly in the next step. MS:275.2[M+1].
[0196] Step 6: Preparation of 5,5-dideutero-2-(5-fluoro-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester [ka]
[0197] 4-Benzyl-5,5-dideutero-2-(5-fluoro-2-pyridyl)morpholine (5.7 g, 20.78 mmol) and di-tert-butyl dicarbonate (9.07 g, 41.56 mmol) were dissolved in ethanol (200 mL), and 10% palladium carbon (1 g, containing 50% w / w water) was added under the protection of nitrogen gas. The mixture was reacted by stirring at 26 ° C for 12 hours under a hydrogen gas atmosphere (1 atm). The catalyst was removed by filtration, and the liquid phase was evaporated to dryness to obtain a crude product. The residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 100: 0 to 80: 20) to obtain the target product 5,5-dideutero-2-(5-fluoro-2-pyridyl)morpholine-4-carboxylate tert-butyl ester (3.43 g, yield: 58.06%). MS:285.2[M+1].
[0198] Step 7: Preparation of (S)-2-(5-fluoropyridin-2-yl)morpholine-5,5-d2 and (R)-2-(5-fluoropyridin-2-yl)morpholine-5,5-d2 [ka]
[0199] tert-Butyl-2-(5-fluoropyridin-2-yl)morpholine-4-carboxylate-5,5-d2. The compound was separated by chiral column (chromatography column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=95:5, run time (min): 10, linear mode: isocratic) to give compound 17-P1 (1.5g, RT (retention time) = 3.340min), compound 17-P2 (1.4g, RT (retention time) = 3.773min), With reference to Example 10, the Boc protecting group was removed to obtain compound 17-1 from compound 17-P1, and compound 17-2 from compound 17-P2. Compound 17-1:MS:185.1[M+1]. Compound 17-2:1H NMR(400MHz,DMSO)δ 8.52-8.43(m,1H),7.77-7.64(m,1H),7.55-7.41(m,1H),4.48-4.35(m,1H), 3.94-3.82(m,1H),3.65-3.56(m,1H),3.13-3.04(m,1H),2.56-2.45(m,1H). MS: 185.1 [M+1].
[0200] Example 18 5,5-Dimethyl-2-(pyridin-2-yl)morpholine [ka]
[0201] Using 2-bromo-1-(pyridin-2-yl)ethan-1-one as a raw material, 5,5-dimethyl-2-(pyridin-2-yl)morpholine was obtained by referring to Example 4. MS:193.1[M+1].
[0202] Example 19 Step 1: Preparation of 3-fluoro-2-methyl-6-vinylpyridine [ka]
[0203] 6-Bromo-3-fluoro-2-methylpyridine (0.1g, 526.28μmol), potassium vinyl trifluoroborate (84.59mg, 631.54μmol) and cesium carbonate (514.42mg, 1.58mmol) were dissolved in 1'4-dioxane (5mL) and water (2mL), and 1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (19.25mg, 26.31μmol) was added under the protection of nitrogen gas. The mixture was stirred at 90°C for 6 hours under the protection of nitrogen gas. The reaction was quenched by adding saturated saline (50mL) to the mixture, extracted with ethyl acetate (30mL x 2), and the organic phases were combined, washed successively with saturated saline (50mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with petroleum ether:ethyl acetate=100:0 to 90:10) to obtain the target product 3-fluoro-2-methyl-6-vinylpyridine (50 mg, yield: 69.27%). MS m / z(ESI):138.1 [M+1]
[0204] Step 2: Preparation of 3-fluoro-2-methyl-6-(oxime-2-yl)pyridine [ka]
[0205] 3-Fluoro-2-methyl-6-vinylpyridine (0.6 g, 4.37 mmol) was dissolved in water (10 mL) and tert-butanol (5 mL), and N-bromosuccinimide (856.48 mg, 4.81 mmol) was added. The mixture was stirred at 25° C. for 1 hour to react. It was then cooled to 0° C., and a solution of sodium hydroxide (524.92 mg, 13.12 mmol) in water (2 ml) was added, and the mixture was stirred at 0° C. for 1 hour to react. LCMS showed the reaction was complete, and the reaction solution was extracted with ethyl acetate (30 mL×2), and the organic phase was separated, washed with saturated brine (30 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain crude 3-fluoro-2-methyl-6-(oxiran-2-yl)pyridine (0.6 g). The crude was used directly in the next step. MS m / z(ESI):154.1[M+1]
[0206] Step 3: Preparation of 2-[benzyl(2-hydroxyethyl)amino]-1-(5-fluoro-6-methyl-2-pyridyl)ethanol [ka]
[0207] 2-(benzylamino)ethanol (651.60 mg, 4.31 mmol) was dissolved in isopropanol (15 mL), and a solution of 3-fluoro-2-methyl-6-(oxiran-2-yl)pyridine (0.6 g, 3.92 mmol) in isopropanol (3 mL) was added at 90° C. under the protection of nitrogen gas. The mixture was reacted by stirring at 90° C. for 12 hours. The mixture was concentrated under reduced pressure. The residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 100:0 to 20:80) to obtain the target product 2-[benzyl(2-hydroxyethyl)amino]-1-(5-fluoro-6-methyl-2-pyridyl)ethanol (0.77 g, yield: 64.58%). MS m / z(ESI):305.2[M+1]
[0208] Step 4: Preparation of 4-benzyl-2-(5-fluoro-6-methyl-2-pyridyl)morpholine [ka]
[0209] 2-[benzyl(2-hydroxyethyl)amino]-1-(5-fluoro-6-methyl-2-pyridyl)ethanol (0.77 g, 2.53 mmol) was dissolved in tetrahydrofuran (15 mL), and sodium hydrogen (202.37 mg, 5.06 mmol, 60% w / w) was added under cooling with an ice-water bath and protection of nitrogen gas. The mixture was stirred at 0° C. for 1 hour to react. Then, 1-(p-toluenesulfonyl)imidazole (562.31 mg, 2.53 mmol) was added. The mixture was stirred at 23° C. for 12 hours to react. The reaction was quenched by adding saturated saline (50 mL) to the mixture at 0° C., extracted with ethyl acetate (30 mL×2), and the organic phases were combined, washed successively with saturated saline (50 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with petroleum ether:ethyl acetate=100:0 to 70:30) to obtain the desired product 4-benzyl-2-(5-fluoro-6-methyl-2-pyridyl)morpholine (0.36 g, yield: 49.69%). MS m / z(ESI):287.2[M+1]
[0210] Step 5: Preparation of 2-(5-fluoro-6-methyl-2-pyridyl)morpholine [ka]
[0211] 4-Benzyl-2-(5-fluoro-6-methyl-2-pyridyl)morpholine (180 mg, 628.62 μmol) was dissolved in EtOH (15 mL) and Pd / C (66.90 mg, 628.62 μmol) was added under the protection of nitrogen gas. The mixture was stirred at 25° C. for 12 hours under hydrogen gas atmosphere (1 atm). The catalyst was removed by filtration and the liquid phase was evaporated to dryness to obtain the desired product 2-(5-fluoro-6-methyl-2-pyridyl)morpholine (70 mg, yield: 56.75%). MS m / z(ESI):197.1[M+1]
[0212] Step 6: Preparation of 2-(5-fluoro-6-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester [ka]
[0213] 2-(5-Fluoro-6-methyl-2-pyridyl)morpholine (150 mg, 764.44 μmol) and triethylamine (232.06 mg, 2.29 mmol, 319.64 μL) were dissolved in dichloromethane (10 mL), and di-tert-butyl dicarbonate (250.26 mg, 1.15 mmol) was added under the protection of nitrogen gas. The mixture was reacted by stirring at 25 ° C for 1 hour. The mixture was concentrated under reduced pressure. The residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 100: 0 to 80: 20) to obtain the target product 2-(5-fluoro-6-methyl-2-pyridyl)morpholine-4-carboxylate tert-butyl ester (0.2 g, yield: 88.29%). MS m / z(ESI):297.2[M+1]
[0214] Step 7: Preparation of (S)-2-(5-fluoro-6-methyl-2-pyridyl)morpholine and (R)-2-(5-fluoro-6-methyl-2-pyridyl)morpholine [ka]
[0215] 2-(5-Fluoro-6-methyl-2-pyridyl)morpholine-4-carboxylic acid tert-butyl ester was chirally resolved (chromatography column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=70:30, run time (min): 10, linear mode: isocratic) to obtain compound 19-P1 (80mg, RT (retention time) = 2.213min) and compound 19-P2 (98mg, RT (retention time) = 2.523min).
[0216] With reference to Example 10, the Boc protecting group was removed to obtain compound 19-1 from compound 19-P1, and compound 19-2 from compound 19-P2. Compound 19-1:MS:197.1[M+1]. Compound 19-2:MS:197.1[M+1].
[0217] Example 20 2-(6-(trifluoromethyl)pyridin-2-yl)morpholine [ka]
[0218] Step 1: 2-Trifluoromethyl-6-(oxiran-2-yl)pyridine [ka]
[0219] Starting from 6-trifluoromethylpyridine-2-carboxaldehyde, 2-trifluoromethyl-6-(oxiran-2-yl)pyridine was obtained by referring to Step 1 of Example 10. MS m / z(ESI):243.14 [M+1]
[0220] Step 2: 2-(benzyl(2-hydroxyethyl)amino)-1-(6-(trifluoromethyl)pyridin-2-yl)ethan-1-ol [ka]
[0221] At room temperature, 2-(benzylamino)ethanol (1.10g, 7.30mmol) was dissolved in isopropanol (40mL), heated to 90℃, and 2-trifluoromethyl-6-(oxiran-2-yl)pyridine (1.15g, 6.08mmol) in isopropanol (40mL) was added dropwise, reacted at 90℃ for 14 hours, cooled to room temperature, LCMS showed the reaction was complete, the reaction solution was diluted with ethyl acetate (60mL) and washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude was purified by high-speed silica gel chromatography (eluted with petroleum ether:ethyl acetate=50:50-30:70) to obtain the target product (1.90g) as a pale yellow oil, with a yield of 91.8%. MS:341.14[M+1].
[0222] Step 3: 4-benzyl-2-(6-(trifluoromethyl)pyridin-2-yl)morpholine [ka]
[0223] Under ice bath, 2-(benzyl(2-hydroxyethyl)amino)-1-(6-(trifluoromethyl)pyridin-2-yl)ethan-1-ol (0.77 g, 2.26 mmol) was dissolved in tetrahydrofuran (40 mL), purged with nitrogen gas, and sodium hydrogen (181.00 mg, 4.52 mmol, 60%) was added. Add 1-(4-toluenesulfonyl)imidazole (553.14mg, 2.49mmol) in tetrahydrofuran (2mL) dropwise, stir at room temperature for 2 hours, TLC shows the reaction is complete, quench the reaction with saturated ammonium chloride solution, and extract with ethyl acetate, combine the organic phase, dry the organic phase with anhydrous sodium sulfate, filter, spin-dry, and purify the crude product by high-performance silica gel chromatography column (eluted with PE:EA=90:10-70:30) to obtain the desired product (0.32g) as a yellow oil, with a yield of 43.8%. MS:323.14[M+1].
[0224] Step 4: 2-(6-(trifluoromethyl)pyridin-2-yl)morpholine [ka]
[0225] At room temperature, 4-benzyl-2-(6-(trifluoromethyl)pyridin-2-yl)morpholine (0.30 g, 930.74 μmol) was dissolved in dichloromethane (10 mL) and 1-chloroethyl chloroformate (532.27 mg, 3.72 mmol) was added, stirred at room temperature for 2 hours, spin-dried, the residue was dissolved in methanol (10 mL), heated to 70° C., reacted for 1 hour, cooled to room temperature, LCMS showed the reaction was complete, spin-dried, the residue was used directly in the next step (0.28 g), the yield is 99.0%. MS:233.08[M+1].
[0226] Step 5: tert-Butyl 2-(6-(trifluoromethyl)pyridin-2-yl)morpholine-4-carboxylate [ka]
[0227] At room temperature, 2-(6-(trifluoromethyl)pyridin-2-yl)morpholine (0.33 g, 1.23 mmol, hydrochloride) was dissolved in DCM (10 mL), and N,N-diethylethylamine (621.46 mg, 6.14 mmol, 856.60 μL) and tert-butoxycarbonyl tert-butyl carbonate (402.53 mg, 1.84 mmol) were added and stirred at room temperature overnight. TLC showed the completion of the reaction, the reaction solution was washed with saturated sodium bicarbonate solution and then with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 90: 10 to 70: 30) to obtain the target product (0.30 g) as a pale yellow oil, with a yield of 73.5%. MS:277.08[M-55].
[0228] Step 6: 2-(6-(trifluoromethyl)pyridin-2-yl)morpholine [ka]
[0229] The Boc protecting group was removed with reference to Example 10 to obtain the desired product (0.04 g). MS:233.08[M+1].
[0230] Example 21 [ka] The product 2-(3-fluoro-5-methylpyridin-2-yl)morpholine was obtained in the same manner as in Step 1 to Step 5 of Example 19. MS: 197.10 [M+1].
[0231] Example 22 2-(3-fluoro-6-methylpyridin-2-yl)morpholine [ka]
[0232] Step 1: 3-Fluoro-6-methyl-2-vinylpyridine [ka]
[0233] At room temperature, 2-bromo-3-fluoro-6-methyl-pyridine (5.0 g, 26.31 mmol), cesium carbonate (17.15 g, 52.63 mmol), [1,1-bis(diphenylphosphino)ferrocene]palladium dichloride (1.93 g, 2.63 mmol), potassium trifluoro(vinyl)borane (4.23 g, 31.58 mmol) were dissolved in water (12 mL) and 1,4-dioxane (60 mL), purged with nitrogen gas, heated to 90° C., reacted for 14 hours, and cooled to room temperature. LCMS showed the reaction was complete, the reaction solution was diluted with ethyl acetate and washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was purified by high-speed silica gel chromatography (eluted with petroleum ether:ethyl acetate=90:10-70:30) to give the desired product (1.70 g) as a colorless oil, the yield was 47.1%. MS: 138.06 [M+1].
[0234] Step 2: 3-Fluoro-6-methyl-2-(oxiran-2-yl)pyridine [ka]
[0235] At room temperature, 3-fluoro-6-methyl-2-vinylpyridine (1.70g, 12.39mmol) was dissolved in water (40mL) and tert-butanol (20mL), and N-bromosuccinimide (2.32g, 13.01mmol) was added, heated to 40℃, reacted for 1 hour, and cooled in an ice bath, and an aqueous solution of sodium hydroxide (1.49g, 37.18mmol) was added dropwise, and the reaction solution was stirred for another 1 hour, and TLC showed the completion of the reaction, and the reaction solution was diluted with water and extracted with ethyl acetate, and the organic phase was combined, and the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 90: 10 to 70: 30) to obtain the target product (1.20g) as a colorless oil, with a yield of 63.2%. MS: 154.06 [M+1].
[0236] Step 3: 2-(3-fluoro-6-methylpyridin-2-yl)morpholine [ka]
[0237] Starting from 3-fluoro-6-methyl-2-(oxiran-2-yl)pyridine, 2-(3-fluoro-6-methylpyridin-2-yl)morpholine was obtained according to steps 2, 3, 4, 5, and 6 of Example 20. MS: 197.10 [M+1].
[0238] Example 23 [ka] Using 3-methylpyridine aldehyde as a raw material, tert-butyl 2-(3-methylpyridin-2-yl)morpholine-4-carboxylate was obtained by referring to Example 20, and tert-butyl 2-(3-methylpyridin-2-yl)morpholine-4-carboxylate was subjected to chiral separation under the following conditions (chromatography column: CHIRALPAK IC 4.6*250mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=70:30, run time (min): 10, linear mode: isocratic), and 23-P1 (RT (retention time) = 2.560min) and 23-P2 (RT (retention time) = 3.680min) were obtained. With reference to Example 10, the Boc protecting group was removed to obtain compound 23-1 from compound 23-P1, and compound 23-2 from compound 23-P2. Compound 23-1 MS:179.1[M+1]. Compound 23-2 MS:179.1[M+1].
[0239] Example 24 [ka] Using 1-(pyridin-2-yl)ethan-1-one as a raw material, tert-butyl-2-(5-fluoropyridin-2-yl)morpholine-4-carboxylate-5,5-d2 was obtained by referring to Example 20. The compound was separated by a chiral column (chromatography column: CHIRALPAK IC 4.6*250mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:IPA=70:30; run time (min): 10, linear mode: isocratic) to obtain 24-P1 (RT (retention time) = 4.907min) and 24-P2 (RT (retention time) = 6.520min). With reference to Example 10, the Boc protecting group was removed to obtain compound 24-1 from compound 24-P1, and compound 24-2 from compound 24-P2. Compound 24-1 MS:179.1[M+1]. Compound 24-2 MS:179.1[M+1].
[0240] Example 25 [ka] Using 1-(5-chloropyridin-2-yl)ethan-1-one as raw material, 4-benzyl-2-(5-chloropyridin-2-yl)morpholine is obtained by referring to Example 4. The compound 4-benzyl-2-(5-chloropyridin-2-yl)morpholine is separated by chiral column (chromatography column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=70:30, run time (min): 10, linear mode: isocratic), to obtain compound 25-P1 (RT (retention time) = 2.543min), compound 25-P2 (RT (retention time) = 2.843min). Referring to step 6 of Example 4, compound 25-P1 was debenzylated to give compound 25-1, and compound 25-P2 was debenzylated to give compound 25-2. Compound 25-1 MS:199.1[M+1]. Compound 25-2 MS:199.1[M+1].
[0241] Example 26 2-(pyridin-2-yl)-1,4-oxazepine [ka]
[0242] Using 2-bromo-1-(pyridin-2-yl)ethan-1-one as a raw material, 2-(pyridin-2-yl)-1,4-oxazepine was obtained by referring to Example 4. MS: 179.1 [M+1].
[0243] Example 27 [ka] Step 1: Preparation of 4-benzyl-2-(6-chloropyridin-3-yl)morpholine [ka]
[0244] Using 2-chloro-1-(6-chloropyridin-3-yl)ethan-1-one as a raw material, 4-benzyl-2-(6-chloropyridin-3-yl)morpholine was obtained by referring to steps 3 to 5 of Example 4. MS:289.1[M+1].
[0245] Step 2: Preparation of N-(5-(4-benzylmorpholin-2-yl)pyridin-2-yl)-1,1-diphenylmethylamine [ka]
[0246] 4-benzyl-2-(6-chloropyridin-3-yl)morpholine (0.3g, 1.04mmol), diphenylmethylamine (225.94mg, 1.25mmol), 1,1'-binaphthyl-2,2'-diphenylphosphino (BINAP) (103mg, 166μmol) and cesium carbonate (676.98mg, 2.08mmol) were dissolved in 1'4-dioxane (25mL), and tri(dibenzylideneacetone)dipalladium (76.11mg, 83.11μmol) was added under the protection of nitrogen gas. The mixture was stirred at 110°C for 5 hours to react. The reaction was quenched by adding saturated saline (50mL) to the mixture, extracted with ethyl acetate (30mL x 2), and the organic phases were combined, washed successively with saturated saline (50mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with petroleum ether:ethyl acetate = 100:0 to 60:40) to obtain the desired product N-(5-(4-benzylmorpholin-2-yl)pyridin-2-yl)-1,1-diphenylmethylamine (0.38 g, 876.50 μmol, yield: 84.37%). MS: 434.2 [M+1].
[0247] Step 3: Preparation of 5-(4-benzylmorpholin-2-yl)pyridin-2-amine [ka]
[0248] N-(5-(4-benzylmorpholin-2-yl)pyridin-2-yl)-1,1-diphenylmethylamine (0.3 g, 691.97 μmol) was dissolved in tetrahydrofuran (1 mL) and methanol (5 mL), and aqueous hydrochloric acid (2 M, 6 mL) was added under the protection of nitrogen gas. The mixture was stirred at 23 ° C for 12 hours to react. The mixture was quenched by adding saturated aqueous sodium bicarbonate solution (50 mL), extracted with ethyl acetate (50 mL × 3), and the organic phases were combined, washed successively with saturated saline (50 mL × 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with dichloromethane:methanol = 100:0 to 95:5) to obtain the target product 5-(4-benzylmorpholin-2-yl)pyridin-2-amine (0.1 g, 371.28 μmol, yield: 53.65%). MS:270.2[M+1].
[0249] Step 4: Preparation of 5-morpholin-2-ylpyridin-2-amine [ka]
[0250] 5-(4-benzylmorpholin-2-yl)pyridin-2-amine (24 mg, 89.11 μmol) was dissolved in EtOH (10 mL) and 10% palladium carbon (6.00 mg, containing 50% w / w water) was added under the protection of nitrogen gas. The mixture was stirred at 23° C. for 1 hour under hydrogen gas atmosphere (1 atm). The catalyst was removed by filtration and the liquid phase was evaporated to dryness to obtain the desired product 5-morpholin-2-ylpyridin-2-amine (15.9 mg, 81.62 μmol, yield: 91.60%). 1H NMR(400MHz,CDCl3)δ 8.03(d,J=2.3Hz,1H),7.46(dd,J=8.4,2.3Hz,1H),6.48(d,J=8.4Hz,1H),4.53-4.40(br,2H), 4.40-4.31(m,1H),4.05-3.91(m,1H),3.83-3.67(m,1H),3.05-2.92(m,2H),2.92-2.73(m,2H). MS:180.1[M+1].
[0251] Example 28 2-(phenyl-4-d)morpholine [ka]
[0252] 2-(4-Bromophenyl)morpholine (220 mg, 908.67 μmol) and cesium carbonate (740.16 mg, 2.27 mmol) were dissolved in deuterated methanol (5 mL), and 1,1'-bisdiphenylphosphinoferrocenedichloropalladium (66.49 mg, 90.87 μmol) was added under the protection of nitrogen gas. The mixture was stirred at 80°C and reacted for 16 hours. The reaction solution was evaporated to dryness, and the crude product was separated by high-speed liquid chromatography to obtain the product 2-(phenyl-4-d)morpholine (75 mg, 50% yield). 1 H NMR(400MHz,DMSO)δ 7.38-7.25(m,4H),4.42-4.30(m,1H),3.93-3.79(m,1H),3.64-3.53(m,1H),2.95-2.83(m,1H),2.79-2.70(m,2H),2.51-2.50(m,1H). MS: 165.1 [M+1].
[0253] The compounds were then separated by a chiral column (chromatography column: CHIRALPAK AD-H 4.6*250mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH:MeOH:DEA = 70:15:15:0.1%, run time (min): 12, linear mode: isocratic) to give compound 1-1 (30mg, RT (retention time) = 5.630min) and compound 1-2 (30mg, RT (retention time) = 6.743min). Compound 28-1:1H NMR(400MHz,DMSO)δ 7.38-7.25(m,4H),4.42-4.30(m,1H),3.93-3.79(m,1H),3.64-3.53(m,1H),2.95-2.83(m,1H),2.79-2.70(m,2H),2.51-2.50(m,1H). MS: 165.1 [M+1]. Compound 28-2:1H NMR(400MHz,DMSO)δ 7.38-7.25(m,4H),4.42-4.30(m,1H),3.93-3.79(m,1H),3.64-3.53(m,1H),2.95-2.83(m,1H),2.79-2.70(m,2H),2.51-2.50(m,1H). MS: 165.1 [M+1].
[0254] Example 29 2-Phenylmorpholine-5,5-d2 [ka]
[0255] Under ice bath, 6-phenyl-morpholin-3-one (500 mg, 2.82 mmol) was dissolved in THF (10 mL), and deuterated borane tetrahydrofuran solution (0.75 M, 15 mL, 11.29 mmol) was added, nitrogen gas was replaced, and the mixture was heated to 70 ° C. and reacted for 2 hours, cooled to room temperature, and LCMS showed the completion of the reaction. The reaction solution was quenched with methanol, and heated to 70 ° C. and reacted for 2 hours, cooled to room temperature, spin-dried, the residue was dissolved in ethyl acetate, and washed successively with saturated ammonium chloride solution and saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was purified by high-speed silica gel chromatography (eluted with petroleum ether: ethyl acetate = 85: 15 to 50: 50) to obtain the target product 2-phenylmorpholin-5,5-d2 (396 mg, yield: 84.9%). MS:166.1[M+1].
[0256] Example 30 2-(phenyl-4-d)morpholine-5,5-d2 [ka]
[0257] Using 6-(4-chlorophenyl)-3-morpholinone as a raw material, 2-(phenyl-4-d)morpholine-5,5-d2 was synthesized by referring to Examples 29 and 28. MS: 167.1 [M+1].
[0258] Example 31 2-(phenyl-d5)morpholine-5,5-d2 [ka]
[0259] Using 6-(phenyl-d5)morpholin-3-one (prepared by a known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332") as a raw material, 2-(phenyl-d5)morpholine-5,5-d2 was synthesized with reference to Example 29. MS: 171.1 [M+1].
[0260] Example 32 2-(p-benzyl)morpholine-5,5-d2 [ka]
[0261] Starting from 6-(p-benzyl)morpholin-3-one, 2-(p-benzyl)morpholine-5,5-d2 was synthesized by referring to Example 29. MS:180.1[M+1].
[0262] Example 33 2-(4-fluorophenyl)morpholine-5,5-d2 [ka]
[0263] Method 1: Using 6-(4-fluorophenyl)morpholin-3-one (prepared by a known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332") as a raw material, 2-(4-fluorophenyl)morpholine-5,5-d2 was synthesized with reference to Example 29. MS: 184.1 [M+1].
[0264] Method 2: Step 1: 2-(4-fluorophenyl)oxirane [ka]
[0265] Under ice bath, trimethylsulfoxonium iodide (106.39g, 483.43mmol) was dissolved in dimethylsulfoxide (200mL), and tert-butoxide (49.18g, 438.31mmol) was added, replaced with nitrogen gas, stirred at room temperature for 1 hour, and 4-fluorobenzaldehyde (40g, 322.29mmol) in dimethylsulfoxide (200mL) was added and stirred at room temperature for 1 hour. TLC showed the completion of the reaction, the reaction solution was quenched with saturated saline, the reaction solution was extracted with ethyl acetate, the organic phase was combined, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the crude was purified by high-performance silica gel chromatography column (eluted with PE:EA=95:5-90:10) to obtain the target product (19.5g, yield: 43.8%) as a colorless oil.
[0266] Step 2: 2-(benzylamino)-1-(4-fluorophenyl)ethan-1-ol [ka]
[0267] 2-(4-fluorophenyl)oxirane (14.5g, 104.97mmol) was stirred at room temperature, and benzylamine (33.74g, 314.90mmol) was added, nitrogen gas was replaced, and the mixture was heated to 80°C, reacted for 6 hours, cooled to room temperature, and stirred at room temperature for 7 hours. A white solid precipitated, and 120ml of water was added, stirred at room temperature for 1 hour, filtered, and the solid was washed twice with water, twice with petroleum ether, and dried. The solid was used directly in the next step (15.8g, yield: 61.4%). MS:246.1[M+1].
[0268] Step 3: N-benzyl-2-chloro-N-(2-(4-fluorophenyl)-2-hydroxyethyl)acetamide [ka]
[0269] Under ice bath, 2-(benzylamino)-1-(4-fluorophenyl)ethan-1-ol (12.5g, 50.96mmol) was dissolved in dichloromethane (100mL), and N,N-diethylethylamine (15.47g, 152.88mmol, 21.32mL) and chloroacetyl chloride (8.06g, 71.34mmol) were added in sequence, and the mixture was stirred at room temperature for 2 hours. LCMS showed the reaction was complete, the reaction solution was diluted with dichloromethane and washed with saturated saline, the organic phase was dried over anhydrous sodium sulfate, filtered, spin-dried, and the residue was used directly in the next step (16.4g, yield: 100%). MS:322.1[M+1].
[0270] Step 4: 4-benzyl-6-(4-fluorophenyl)morpholin-3-one [ka]
[0271] Under ice bath, N-benzyl-2-chloro-N-(2-(4-fluorophenyl)-2-hydroxyethyl)acetamide (16.4 g, 50.97 mmol) was dissolved in tetrahydrofuran (150 mL) and tert-butoxide (11.44 g, 101.94 mmol) was added, stirred at room temperature for 2 hours, LCMS showed the reaction was completed. The reaction was quenched with saturated sodium chloride solution and extracted with ethyl acetate, the organic phases were combined, the organic phase was dried with anhydrous sodium sulfate solution, filtered, spin-dried, and the crude was purified by high-speed silica gel chromatography (eluted with petroleum ether:ethyl acetate = 80:20 to 60:40) to obtain the desired product (12.4 g, yield: 85.3%) as a yellow solid. MS:286.1[M+1].
[0272] Step 5: 4-benzyl-2-(4-fluorophenyl)morpholine-5,5-d2 [ka]
[0273] In an ice-salt bath, deuterated lithium tetrahydroaluminate (1.15 g, 27.34 mmol) was dissolved in tetrahydrofuran (50 mL), nitrogen gas was replaced, and a mixed solution of 4-benzyl-6-(4-fluorophenyl)morpholin-3-one (6.0 g, 21.03 mmol) and aluminum trichloride (3.65 g, 27.34 mmol) in tetrahydrofuran (50 mL) was added dropwise. After the addition was completed, the reaction solution was reacted in an ice bath for 2 hours, and then stirred at room temperature overnight. LCMS showed the completion of the reaction, and the reaction solution was Quench with water (1.15mL), add dilute hydrochloric acid (1N, 10mL) to clarify the reaction, adjust the solution pH to 8-9 with 10% aqueous sodium hydroxide solution, filter, wash the filter residue with ethyl acetate, layer the filtrate, wash the organic phase with saturated brine, dry the organic phase with anhydrous sodium sulfate, filter, spin dry, and separate the crude by Flash column chromatography (PE:EA=10:1-4:1) to obtain the desired product (5.5g, yield: 95.7%) as a colorless oil. MS:274.1[M+1].
[0274] Step 6: tert-Butyl 2-(4-fluorophenyl)morpholine-4-carboxylate-5,5-d2 [ka]
[0275] At room temperature, tert-butoxycarbonyl tert-butyl carbonate (7.90 g, 36.22 mmol), 4-benzyl-2-(4-fluorophenyl)morpholine-5,5-d2 (5.5 g, 20.12 mmol), palladium / carbon (1.05 g, 8.65 mmol) were dissolved in ethanol (80 mL), hydrogen gas was replaced, and the mixture was stirred at room temperature for 14 hours. LCMS showed the completion of the reaction, and the mixture was filtered, spin-dried, and the residue was separated by Flash column chromatography (eluted with PE:EA=96:4 to 87:13) to obtain the desired product (4.8 g, yield: 84.2%) as a colorless oil. MS:228.1[M-55].
[0276] Step 7: (R)-2-(4-fluorophenyl)morpholine-5,5-d2 and (R)-2-(4-fluorophenyl)morpholine-5,5-d2 [ka]
[0277] Compound tert-butyl 2-(4-fluorophenyl)morpholine-4-carboxylate-5,5-d2 was separated by a chiral column (chromatography column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=90:10, run time (min): 10, linear mode: isocratic) to obtain compound 19-P1 (2.0g, RT (retention time) = 3.423min), compound 19-P2 (2.1g, RT (retention time) = 3.860min), Compound 6-P1 was dissolved in 1'4-dioxane, hydrochloric acid / dioxane (4M) was added, and the reaction was stirred at room temperature for 1 h. The solvent was spun dry, saturated aqueous sodium bicarbonate was added, and the organic phase was extracted with dichloromethane and pumped with an oil pump to give compound 33-1. The Boc protecting group was removed from compound 33-P2 in the same manner to give compound 33-2. Compound 33-1:1H NMR(400MHz,DMSO)δ 7.45-7.30(m,2H),7.24-7.02(m,2H),4.43-4.27(m,1H),3.91-3.80(m,1H),3.62-3.49(m,1H),2.94-2.84(m,1H),2.53-2.39(m,1H). MS: 184.1 [M+1]. Compound 33-2:MS:184.1[M+1].
[0278] Example 34 2-Phenyl-1,4-oxazepine-5,5-d2 [ka]
[0279] Using 2-phenyl-1,4-oxazepine-5-one (produced by a known method "ACS Combinatorial Science, 2016, vol. 18, #9, p. 569-574") as a raw material, 2-phenyl-1,4-oxazepine-5,5-d2 was synthesized with reference to Example 29. MS:180.1[M+1].
[0280] Example 35 2-(phenyl-4-d)-1,4-oxazepine [ka]
[0281] Using 2-(4-bromophenyl)-1,4-oxazepin-5-one (produced by a known method "ACS Combinatorial Science, 2016, vol. 18, #9, p. 569-574") as a raw material, 2-(phenyl-4-d)-1,4-oxazepin was synthesized by referring to Example 29 and Example 1. MS: 179.1 [M+1].
[0282] Example 36 N,N-Dimethyl-4-(morpholin-2-yl-5,5-d2)aniline [ka]
[0283] Using 6-(4-(dimethylamino)phenyl)morpholin-3-one (prepared by a known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332") as a raw material, N,N-dimethyl-4-(morpholin-2-yl-5,5-d2)aniline was obtained by referring to Example 29. MS:209.2[M+1].
[0284] Example 37 2-(4-(methoxy-d3)phenyl)morpholine [ka]
[0285] 4-(morpholin-2-yl)phenol (0.3 g, 1.67 mmol) was dissolved in anhydrous tetrahydrofuran (15 mL) and sodium hydrogen (140.60 mg, 3.52 mmol, 60% w / w) was added under ice bath and nitrogen gas protection. The mixture was stirred in ice bath for 10 minutes, and then deuterated iodomethane (218.38 mg, 1.51 mmol) was added. The reaction solution was stirred at room temperature overnight. The mixture was cooled to 5° C. and quenched with saturated saline (5 mL), the organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under pressure to obtain the crude product. The crude product was separated by high-speed liquid separation to obtain the product 2-(4-(methoxy-d3)phenyl)morpholine (81 mg, yield: 24.66%). MS: 197.1 [M+1].
[0286] Example 38 2-(phenyl-2-d)morpholine [ka]
[0287] Using 2-(2-bromophenyl)morpholine as a raw material, 2-(phenyl-2-d)morpholine was synthesized by referring to Example 28. MS: 165.1 [M+1].
[0288] Example 39 2-(phenyl-3-d)morpholine [ka]
[0289] Using 2-(3-bromophenyl)morpholine as a raw material, 2-(phenyl-3-d)morpholine was synthesized with reference to Example 28. MS: 165.1 [M+1].
[0290] Example 40 2-(phenyl-2,4-d2)morpholine [ka]
[0291] Using 6-(2,4-dibromophenyl)morpholin-3-one (prepared by a known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332") as a raw material, 2-(phenyl-2,4-d2)morpholine was synthesized by referring to Example 29 and Example 28. MS:166.1[M+1].
[0292] Example 41 2-(phenyl-2,4,6-d3)morpholine [ka]
[0293] Using 6-(2,4,6-trichlorophenyl)morpholin-3-one (prepared by a known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332") as a raw material, 2-(phenyl-2,4,6-d3)morpholine was synthesized by referring to Example 29 and Example 28. MS: 167.1 [M+1].
[0294] Example 42 2-(phenyl-4-d)morpholine-2-d [ka]
[0295] Using 6-(4-bromophenyl)morpholin-3-one-6-d (prepared by the known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332", using sodium deuteride instead of sodium borohydride), 2-(phenyl-4-d)morpholine-2-d was synthesized by referring to Example 29 and Example 28. MS:166.1[M+1].
[0296] Example 43 2-(phenyl-2,4,6-d3)morpholine-5,5-d2 [ka]
[0297] Using 6-(2,4,6-trichlorophenyl)morpholin-3-one (prepared by a known method "Bioorg. Med. Chem. Lett. 26 (2016) 1329-1332") as a raw material, 2-(phenyl-2,4,6-d3)morpholine-5,5-d2 was synthesized by referring to Example 29 and Example 28. MS: 169.1 [M+1].
[0298] Example 44 2-(m-methylphenyl)morpholine-5, 5-d2 [ka]
[0299] Using 6-(m-methyl)-morpholin-3-one as a raw material, compound 2-(m-methylphenyl)morpholine-5, 5-d2 was obtained by referring to Example 29. S: 180.1 [M+1]
[0300] Example 45 2-(3-chlorophenyl)morpholine-5, 5-d2 [ka]
[0301] Starting from 6-(3-chlorophenyl)-morpholin-3-one, compound 2-(3-chlorophenyl)morpholine-5, 5-d2 was obtained with reference to Example 29. MS:200.1[M+1]
[0302] By referring to the resolution method of Example 28, single chiral structure compounds of Examples 29 to 45 were obtained:
[0303] [Table 1-1] [Table 1-2] [Table 1-3]
[0304] Example 46 [ka] 2-(3-Chlorophenyl)morpholine hydrochloride (0.6g, 2.56mmol) and triethylamine (777.98mg, 7.69mmol, 1.07mL) were dissolved in dichloromethane (20.20mL), and di-tert-butyl dicarbonate (727.11mg, 3.33mmol) was added under the protection of nitrogen gas. The mixture was stirred at 18°C for 3 hours to react. The mixture was quenched by adding saturated saline (50mL), extracted with dichloromethane (50mL), and the organic phases were combined, washed successively with saturated saline (50mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by high-performance silica gel chromatography (eluted with petroleum ether:ethyl acetate=100:0 to 80:20) to obtain the desired product tert-butyl 2-(3-chlorophenyl)morpholine-4-carboxylate (0.4 g, 1.34 mmol, yield: 52.42%).
[0305] tert-Butyl 2-(3-chlorophenyl)morpholine-4-carboxylate was separated on a chiral column (chromatographic column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=70:30, run time (min): 10, linear mode: isocratic) to give compound 46-P1 (RT (retention time) = 2.543min) and compound 46-P2 (RT (retention time) = 2.843min).
[0306] The Boc protecting group of compound 46-P1 was removed by step 7 of method 2 in Example 33 to give compound 46-1, and the Boc protecting group of compound 46-P2 was removed by step 7 of method 2 in Example 33 to give compound 46-2. Compound 46-1 MS:198.1[M+1]. Compound 46-2 MS:198.1[M+1].
[0307] Example 47 [ka] Starting from m-methylbenzaldehyde, the product tert-butyl 2-(m-benzyl)morpholine-4-carboxylate was obtained according to Method 2 in Example 33.
[0308] tert-Butyl 2-(m-benzyl)morpholine-4-carboxylate was separated on a chiral column (chromatographic column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=70:30, run time (min): 10, linear mode: isocratic) to give compound 47-P1 (RT (retention time) = 2.807min) and compound 47-P2 (RT (retention time) = 3.300min). The Boc protecting group of compound 47-P1 was removed by step 7 of method 2 in Example 33 to give compound 47-1, and the Boc protecting group of compound 47-P2 was removed by step 7 of method 2 in Example 33 to give compound 47-2. Compound 47-1 MS:178.1[M+1]. Compound 47-2 MS:178.1[M+1].
[0309] Example 48 [ka] Starting from 3-fluorobenzaldehyde, the product tert-butyl 2-(3-fluorophenyl)morpholine-4-carboxylate was obtained according to Method 2 in Example 33.
[0310] tert-Butyl 2-(3-fluorophenyl)morpholine-4-carboxylate was separated on a chiral column (chromatographic column: CHIRALCEL OJ 4.6*150mm, 5μm, detection wavelength (nm): 214, temperature (℃): 35, flow rate (mL / min): 1, mobile phase: Hexane:EtOH=90:10, run time (min): 10, linear mode: isocratic) to give compound 48-P1 (RT (retention time) = 3.077min) and compound 48-P2 (RT (retention time) = 3.467min). The Boc protecting group of compound 48-P1 was removed by step 7 of method 2 in Example 33 to give compound 48-1, and the Boc protecting group of compound 48-P2 was removed by step 7 of method 2 in Example 33 to give compound 48-2. Compound 48-1 MS:182.1[M+1]. Compound 48-2 MS:182.1[M+1].
[0311] Biological Test Evaluation The present invention will be further described below in conjunction with test examples, but these examples are not intended to limit the scope of the present invention.
[0312] Test Example 1: Measurement of the effect of the compounds of the present invention on cAMP content in cells stably expressing the TAAR1 receptor 1.1 Purpose of the experiment: The activating effect of the compound on the TAAR1 receptor is measured.
[0313] 1.2 Laboratory equipment and reagents: 1.2.1 Equipment: 384-well test plate (Perkin Elmer, 6007680) 96-well conical btm PP Plt nature RNASE / Dnase-free plate (ThermoFisher, 249944) EnVision (Perkin Elmer) 1.2.2 Reagents: Fetal Bovine Serum (Gibco, 10999141) Ham's F-12K (Kaighn's) Medium (Hyclone, SH30526.01) Penicillin-Streptomycin, Liquid (Gibco, 15140122) Hygromycin B BSA stabilizer(Perkin Elmer, CR84-100) cAMP kit (Cisbio, 62AM4PEC) IBMX (Sigma, I5879) HEPES (Gibco, 15630080) HBSS (Gibco, 14025076) TrypLE(ThermoFisher, 12604021) DMEM
[0314] 1.3 Experimental Method: 1) Preparation of experimental buffer: 1*HBSS+20mM HEPES+0.1% BSA+500μM IBMX.
[0315] 2) Complete medium: Ham's F12K+10% Fetal Bovine Serum+1*Penicillin-Streptomycin+200μg / mL Hygromycin B for CHO DMEM+10% Fetal Bovine Serum+1*Penicillin-Streptomycin+200μg / mL Hygromycin B for HEK293
[0316] 3) The TAAR1 cell line was cultured in complete medium at 37℃, 5% CO2, digested with TrypLE, and then resuspended in experimental buffer and seeded into a 384 cell culture plate at a seeding density of 8000 cells / 15ul / well.
[0317] 4) Compounds were diluted in experimental buffer and 5 μL of compound was added per well and incubated at 37° C. for 30 minutes.
[0318] 5) cAMP-d2 and Anti-cAMP-Eu3+ were frozen and thawed, and diluted 20-fold with lysis buffer. 10 μL of cAMP-d2 was added to the experimental wells, and 10 μL of Anti-cAMP-Eu3+ was added to the experimental wells. The reaction plate was centrifuged at 200 g at room temperature for 30 s, and then left to stand at 25°C for 1 h, after which data was collected using Envision.
[0319] 1.4 Experimental data processing method: 1)Z' factor=1-3*(SDMax+SDMin) / (MeanMax-MeanMin), 2)CVMax=(SDMax / MeanMax)*100%, 3)CVMin=(SDMin / MeanMin)*100%, 4) S / B=Singal / Background, 5) Compound EC using GraphPad nonlinear fitting equation 50 We calculated:
number
[0320] 1.5 Experimental Results: [Table 2]
[0321] 1.6 Experimental Conclusions: The example compounds shown in the present invention showed good agonist activity in the experiment of the effect on cAMP in cells stably expressing the TAAR1 receptor.
[0322] Test Example 2: Evaluation of efficacy of the compound of the present invention in a phencyclidine (PCP)-induced mouse high spontaneous activity model 2.1 Purpose of the experiment: The purpose of this study is to evaluate the efficacy of compounds in a phencyclidine (PCP)-induced high locomotor activity model in C57BL / 6 mice using the locomotor activity assay.
[0323] 2.2 Experimental animals: C57BL / 6 mice, provided by Shanghai Lingcheng Biological Technology Co., Ltd., male, 6–8 weeks old, 20–24 g, 36 mice.
[0324] 2.3 Experimental equipment: [Table 3]
[0325] [Table 4]
[0326] 2.4 Experimental Method: 2.4.1 Grouping: The day before experimental testing, animals were allowed to acclimate in the experimental room for 8 h.
[0327] On the day of acclimation, animals were randomly assigned to groups according to their body weight.
[0328] 2.4.2 Experimental Dosing: The animals were weighed and administered with a solvent control (20% HP-β-CD) or the compound of the present invention (oral administration). After 30 minutes, the model was prepared (intraperitoneal administration), and the animals were administered with saline or phencyclidine in a volume of 10 mL / kg.
[0329] 2.4.3 Testing: After administration, the animals were placed in an observation box, and their spontaneous activity was detected for 30 minutes. The distance (meters) that the animals moved in the observation box was recorded every 5 minutes.
[0330] After 30 minutes, the animals were taken out for model preparation and placed in the observation box, and the spontaneous activity of the animals was detected for 60 minutes, and the distance (meters) moved by the animals in the observation box was recorded every 5 minutes.
[0331] After the test was completed, the animals were removed and the observation box was wiped down and cleaned with 75% alcohol.
[0332] The test results were exported from the computer.
[0333] 2.4.4 Data Collection and Analysis: Data were collected using Excel software. Two-way or one-way analysis of variance was performed using Prism (Graph pad software, Inc.) software. p<0.05 was considered to indicate a significant difference.
[0334] 2.5 Experimental Results: The effect of the compound on the movement distance in the phencyclidine (PCP)-induced C57BL / 6 mouse high spontaneous activity model is as shown in Table 4. Compared with the solvent control group (20% HP-β-CD + Saline), it can significantly induce high spontaneous activity within 60 minutes after phencyclidine (PCP) model creation and administration. The compound of the present invention, at a dose of 1 to 10 mg / kg, can significantly reduce the total stroke of spontaneous activity within 60 minutes compared with the model creation group (20% HP-β-CD + PCP 5 mg / kg). No other obvious side effects were observed during the experiment.
[0335] [Table 5]
[0336] 2.6 Experimental Conclusions: In this experiment, the inventors evaluated the efficacy of the compound of the present invention in the phencyclidine-induced mouse high locomotor activity model. Phencyclidine (5mg / kg) can significantly induce high locomotor activity within 60 minutes after model preparation and administration, and the compound of the present invention can significantly suppress the high locomotor activity induced by phencyclidine, and significantly reduce the total stroke of locomotor activity within 60 minutes.
[0337] Test Example 3: Pharmacokinetics measurement in Balb / c mice 3.1 Research purpose: Using Balb / c mice as test animals, the pharmacokinetic behavior of the compound of the present invention in the plasma and brain of the mouse body was examined when the compound was orally administered at a dose of 5 mg / kg.
[0338] 3.2 Test Scheme 3.2.1 Test Drugs: Compounds of the invention are self-prepared.
[0339] 3.2.2 Test animals: JPEG2024542057000149.jpg14167
[0340] 3.2.3 Administration: 24 Balb / c mice, male; after an overnight fast, each was administered p.o. at a dose of 5 mg / kg in a dosing volume of 10 mL / kg. 3.2.4 Drug Combinations: Oral drug formulation: 0.5% CMC-Na (1% Tween 80) 5 g of sodium carboxymethylcellulose (HEC, CMC-Na, viscosity: 800 to 1200 Cps) was weighed out and dissolved in 1000 mL of purified water, and 10 g of Tween 80 was added thereto, and the mixture was mixed uniformly and stirred to obtain a clear solution.
[0341] Compound 16-1 was weighed into a 4-mL glass bottle, 2.4 mL of the solution was added, and sonicated for 10 minutes to obtain a colorless clear solution with a concentration of 0.5 mg / mL.
[0342] 3.2.5 Sampling: After the experimental animals were euthanized with CO2, cardiac blood and brain tissue were collected 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration. The blood was placed in an EDTA-2K test tube and centrifuged at 4℃ and 6000 rpm for 6 min to separate the plasma. The brain tissue was washed with pre-cooled PBS, wiped dry, weighed, and all were stored at -80℃ and fed 4 h after administration.
[0343] 3.2.6 Sample Processing: 1) 160 uL of acetonitrile was added to 40 uL of plasma sample to cause precipitation, and after mixing, the sample was centrifuged at 3500 x g for 5 to 20 minutes. The brain tissue was diluted, homogenized, and centrifuged.
[0344] 2) 100 uL of the treated supernatant solution was taken and the concentration of the test compound was analyzed by LC / MS / MS.
[0345] 3.2.7 Liquid phase analysis ● Liquid phase conditions: Shimadzu LC-20AD pump ● Mass spectrometry conditions: AB Sciex API 4000 mass spectrometer ● Chromatography column: phenomenex Gemiu 5um C18 50×4.6mm ● Mobile phase: Liquid A is 0.1% formic acid in water, and Liquid B is acetonitrile. ● Flow rate: 0.8mL / min Elution time: 0-4.0 min. Elution solution:
[0346] [Table 6]
[0347] 3.3 Test Results and Analysis The main pharmacokinetic parameters were calculated using WinNonlin 8.1, and the results of the mouse drug experiment are shown in the table below.
[0348] [Table 7]
[0349] 4. Experimental conclusion: The data in the table show that in pharmacokinetic evaluation experiments in mice, compounds of the present invention showed high exposure following oral administration.
[0350] Test Example 4: Determination of the effect of the compounds of the present invention on calcium flux in cells stably expressing the ADRA1A receptor 1. Purpose of the experiment: The activating effect of the compound on the ADRA1A receptor is measured.
[0351] 2. Laboratory equipment and reagents: 2.1 Equipment: 384-well test plate (Corning, 3764) 384-well compound plate (Corning, 3657) 384-well flipr tetra pipet tips (Molecular Devices, 9000-0764) FLIPR Tetra (Molecular Devices) 2.2 Reagents: Fetal Bovine Serum(AusGeneX, FBS500-S) Ham's F-12K (Kaighn's) Medium (Hyclone, SH30526.01) Penicillin-Streptomycin, Liquid (Gibco, 15140122) Hygromycin B (Invivogen, ant-hg-5) PBS (Solarbio, P1020-500) 1X TrypLE Express Enzyme,no phenol red(500ml)(ThermoFisher Scientific, 12604021) FLIPR Calcium 6 Assay kit (Molecular Devices, R8191) HEPES (Gibco, 15630080) HBSS (Gibco, 14025076)
[0352] 3. Experimental Method: 1) Flp In-CHO-ADRA1A Stable Pool cell line was cultured in complete medium at 37°C, 5% CO2 until it reached 70%-90% conjugation.
[0353] 2) Complete medium: Ham's F12K + 10% FBS + 1*Penicillin-Streptomycin + 600 μg / mL Hygromycin B, Cell inoculation medium: Ham's F12K + 10% FBS, Experimental buffer: 1X HBSS + 20 mM HEPES
[0354] 3) After digestion with TrypLE, the cells were resuspended in inoculation medium and inoculated into a 384-well cell culture plate (Corning, 3764) at 7,000 cells / well and cultured overnight at 37°C, 5% CO2.
[0355] 4) Freeze-thaw 20X Component A to room temperature, dilute it with experiment buffer until the 2X working concentration contained 5 mM Probenecid, and let stand at room temperature.
[0356] 5) Remove the cell culture plate, leave it at room temperature for 10 min, invert and centrifuge at 200 g, centrifuge at RT for 1 s, quickly add 20 μl of Assay buffer to the cell culture plate, then add 20 μl of 2X Component A containing 5 mM Probenecid to each experimental well, centrifuge at 200 g for 3 to 5 sec at RT, and incubate at 37°C for 2 hr.
[0357] 6) The test compound working solution (5X) was removed and allowed to stand at room temperature.
[0358] 7) The cell culture plate was removed and allowed to stand at room temperature for 10 minutes.
[0359] 8) Using the FLIPR Tetra, 10 μl of the compound working solution diluted in step 6) was added to each experimental well and data was collected.
[0360] 4. Experimental data processing method: 1)Z' factor=1-3*(SDMax+SDMin) / (MeanMax-MeanMin), 2)CVMax=(SDMax / MeanMax)*100%, 3)CVMin=(SDMin / MeanMin)*100%, 4) S / B=Singal / Background, 5) Compound EC using GraphPad nonlinear fitting equation 50 We calculated:
number
[0361] 5. Experimental results: [Table 8]
[0362] 6. Experimental conclusion: As can be seen from the data in the table, the compounds of the examples presented in the present invention have weak partial agonist activity in experiments of their effect on calcium flux in cells stably expressing the ADRA1A receptor.
Claims
1. A compound represented by general formula (I), a stereoisomer thereof or a pharma- ceutically acceptable salt thereof, 【Chemistry 1】 Where: R 1 , R 2 , R 3 , R 4 , R 5 and R 9 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Deuterated alkyl groups, C 1-6 Deuterated alkoxy group, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, optionally further substituted; R 6a , R 6b , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium; n is 0, 1, 2 or 3; As a condition, R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , R 6a , R 6b , R 7a , R 7b , R 8a and R 8b wherein at least one substituent of the formula (I) contains D, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.
2. The compound is further represented by general formula (I-1) or (I-2): 【Chemistry 2】 Where: R 1 , R 2 , R 3 , R 4 , R 5 and R 9 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Deuterated alkyl groups, C 1-6 Deuterated alkoxy group, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, optionally selected from deuterium, halogen, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 1-6 Deuterated alkyl groups, C 1-6 Deuterated alkoxy group or C 1-6 may be further substituted with halogenated alkyl groups, R 1 , R 2 , R 3 , R 4 , R 5 and R 9 are each preferably independently hydrogen, deuterium, fluorine, chlorine, a methyl group, a deuterated methyl group, a deuterated methoxy group, or a cyclopropyl group; R 1 , R 2 , R 3 , R 4 , R 5 and R 9 are each independently hydrogen, deuterium, a methyl group, fluorine, or -OCD 3 or -N(CH 3 ) 2 It is more preferable that R 6a , R 6b , R 6a’ , R 6b’ , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium; As a condition, R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , R 6a , R 6b , R 6a’ , R 6b’ , R 7a , R 7b , R 8a and R 8b 2. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, characterized in that at least one of the substituents contains D.
3. The compound further has the general formula (I-3) or (I-4): 【Chemistry 3】 3. The compound according to claim 2, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein:
4. The compound is further represented by the general formula (II): 【Chemistry 4】 R 1 , R 2 and R 5 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-3 Alkyl group, C 1-3 Alkoxy group, C 1-3 Deuterated alkyl groups, C 1-3 Deuterated alkoxy group, C 1-3 Halogenated alkyl group and C 1-3 alkylamino groups; R 7a and R 7b are each independently selected from hydrogen or deuterium; R 1 , R 2 , R 5 , R 7a and R 7b 2. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof, characterized in that at least one of the substituents contains D.
5. The compound is further represented by the general formula (II-2): 【Chemistry 5】 R 1 and R 2 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, or C 1-3 Alkyl group, C 1-3 Alkoxy group, C 1-3 Deuterated alkyl groups, C 1-3 Deuterated alkoxy group, C 1-3 Halogenated alkyl group and C 1-3 alkylamino groups; Preferably, R 1 and R 2 are each independently selected from hydrogen, deuterium, fluorine, chlorine, a dimethylamino group, a methyl group, a methoxy group, a deuterated methyl group and a deuterated methoxy group.
6. The compound further has the general formula (II-2-a) or the general formula (II-2-b): 【Chemistry 6】 6. The compound according to claim 5, wherein the compound is as shown in
7. A compound represented by general formula (I'), a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, 【Chemistry 7】 Where: R 1 , R 2 , R 3 and R 4 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, R 5 , R 6a , R 6b , R 7a , R 7b , R 8a and R 8b are each independently selected from hydrogen or deuterium; As a condition, R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 7a , R 7b , R 8a and R 8b is not hydrogen at the same time, R 1 , R 2 , R 3 Or R 4 each independently represents a halogen, a cyano group, a hydroxyl group, an amino group, or C 1-6 Alkyl group or C 1-6 When selected from halogenated alkyl groups, R 5 , R 6a , R 6b , R 7a , R 7b , R 8a and R 8b At least one of is selected from deuterium, a compound, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.
8. A compound represented by general formula (V), a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof, 【Chemistry 8】 Where: M is N or CR a is selected from R a , R 1 , R 2 , R 3 and R 4 are each independently hydrogen, deuterium, a halogen, an amino group, a hydroxyl group, a cyano group, C 1-6 Alkyl group, C 1-6 Deuterated alkyl groups, C 1-6 Halogenated alkyl group or C 3-12 cycloalkyl groups, R 5 , R 7a and R 7b are each independently selected from hydrogen or deuterium, at least one of which is deuterium, a compound, a stereoisomer thereof, or a pharma- ceutically acceptable salt thereof.
9. R 1 , R 2 , R 3 and R 4 are each independently hydrogen, deuterium, halogen, or C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, The compound, its stereoisomer or its pharma- ceutically acceptable salt according to claim 7 or 8, characterized in that it is preferably hydrogen, deuterium, fluorine, chlorine, a methyl group, a deuterated methyl group or a cyclopropyl group.
10. The compound further has the general formula (VI): 【Chemistry 9】 As shown in M is selected from N or CH; R 1 , R 2 , R 3 and R 4 are each independently hydrogen, deuterium, halogen, or C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups, Preferably, R 1 and R 2 Each independently represents fluorine, C 1-3 Alkyl group, C 1-3 Deuterated alkyl group or C 3-6 cycloalkyl groups; R 3 and R 4 The compound according to claim 8, its stereoisomer or a pharma- ceutically acceptable salt thereof, wherein each of R, R and R is hydrogen.
11. The compound further comprises a compound represented by the general formula (VI-1) or the general formula (VI-2): 【Chemistry 10】 11. The compound according to claim 10, wherein the compound is as shown in Figure 10, a stereoisomer thereof or a pharma- ceutically acceptable salt thereof.
12. 【Fig. 11】 【Chemistry 12】 【Chemistry 13】 3. The compound according to claim 1, its stereoisomer or a pharma- ceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 12, its stereoisomer or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable carriers, diluents or excipients.
14. The pharmaceutical composition according to claim 13, characterized in that the weight percentage of the compound, its stereoisomer or its pharma- ceutically acceptable salt based on the free base is 0.1% to 95%, preferably 0.5% to 85%, more preferably 1% to 60%, even more preferably 5% to 50%, even more preferably 5 to 15%, 15 to 30%, 30 to 40% or 40 to 50%, and even more preferably 5 to 10%, 10 to 15%, 15 to 20%, 20 to 25%, 25 to 30%, 30 to 35%, 35 to 40%, 40 to 45% or 45 to 50%.
15. 15. The pharmaceutical composition according to claim 13 or 14, characterized in that the pharmaceutical composition is selected from a tablet, a capsule, a liquid formulation or an injectable, optionally the pharmaceutical composition comprises a filler, optionally the pharmaceutical composition comprises a disintegrant, optionally the pharmaceutical composition comprises an adhesive, optionally the pharmaceutical composition comprises a surfactant, preferably the pharmaceutical composition comprises one or more of a filler, a disintegrant, an adhesive, a surfactant, a sweetener, a flow agent or a lubricant.
16. The pharmaceutical composition according to any one of claims 13 to 15, wherein the pharmaceutical composition is an immediate release formulation or a sustained release formulation.
17. The compound according to any one of claims 1 to 12, its stereoisomer or pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to any one of claims 13 to 16, wherein the unit dose of the compound is 1 to 1000 mg, preferably 1 to 500 mg, more preferably 1 to 300 mg, even more preferably 3 to 300 mg, even more preferably 5 to 200 mg, or preferably 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 200 mg, 300 mg, 400 mg or 500 mg, based on the free base.
18. Use of the compound according to any one of claims 1 to 12, its stereoisomer or a pharma- ceutically acceptable salt thereof, or the pharmaceutical composition according to claims 13 to 17 in the manufacture of a TAAR1 agonist drug.
19. The use of the compound according to any one of claims 1 to 12, its stereoisomer or its pharma- ceutically acceptable salt, or the pharmaceutical composition according to claims 13 to 17 in the manufacture of a medicament for treating, preventing or controlling a neurological disorder, wherein the neurological disorder is selected from schizophrenia, social dysfunction or psychosis, preferably, schizophrenia is selected from schizophrenia spectrum disorder, acute schizophrenia, chronic schizophrenia, NOS schizophrenia, paranoid schizophrenia, schizophreniform personality disorder or schizotypal personality disorder, preferably, psychosis is selected from delusional disorder, brief psychotic disorder, shared psychotic disorder, mental disorder due to physical illness, medication-induced psychosis, psycho-emotional disorder, aggression, mental confusion, agitated psychosis, Tourette's syndrome, organic or is selected from NOS psychosis, seizures, agitation, post traumatic stress disorder, behavioral confusion, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, movement disorders, Huntington's disease, dementia, affective disorders, anxiety disorders, affective psychosis, depression, major depressive disorder, malaise, bipolar disorder, mania, seasonal affective disorder, attention deficit disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, dizziness, epilepsy, pain, neuropathic pain, neuropathic pain sensitivity state, inflammatory pain, fibromyalgia, migraine, cognitive impairment, movement disorders, restless legs syndrome, multiple sclerosis, sleep disorders, sleep apnea, lethargy attacks, excessive daytime sleepiness, jet lag, lethargy side effect of medication, insomnia, substance abuse dependence, addiction, eating disorders, sexual dysfunction, hypertension, vomiting, Lesche-Nyhane disease, hepatolenticular degeneration, autism or premenstrual dysphoria.
20. A process for producing a compound represented by general formula (VI) according to claim 10, its stereoisomer or a pharma- ceutically acceptable salt thereof, comprising the steps of: 【Chemistry 14】 The method includes the steps of: preparing compound (VI-b) by acylation of compound (VI-a), preparing compound (VI-c) by ring formation under basic conditions, preparing compound (VI-d) after deuteration, preparing compound (VI) by deprotection, and optionally further preparing a pharma- ceutically acceptable salt thereof; where X is selected from halogen, P is selected from amino protecting groups, R 1 , R 2 , R 3 and R 4 is as defined in claim 10.
